Water soluble azoles as broad-spectrum antifungals

专利摘要:
The present invention relates to novel compounds of formula (I) as antifungal agents, their N-oxide forms, pharmaceutically acceptable addition salts and stereochemical isomers: Where L is the following general formula (a); (b); (c); (d); the radicals of (e) or (f), From here, Each Alk independently represents an optionally substituted C 1-6 alkanediyl; n is 1, 2 or 3; Y is O, S or NR 2 ; R 1 represents hydrogen, aryl, Het 1 or optionally substituted C 1-6 alkyl; Each R 2 independently represents hydrogen or C 1-6 alkyl; When R 1 and R 2 are bonded to the same nitrogen atom, they may together form heterocyclic radicals or together may form azido radicals; Each R 3 independently represents hydrogen, hydroxy or C 1-4 alkyloxy; Aryl represents phenyl, naphthalenyl, 1,2,3,4-tetrahydro-naphthalenyl, indenyl or indanyl; Each of these aryl groups may be optionally substituted; Het 1 represents an optionally substituted monocyclic or bicyclic heterocyclic radical, Het 2 is the same as Het 1 and may also be piperazinyl, homopiperazinyl, 1,4-dioxanyl, morpholinyl, thiomorpholinyl; R 6 represents hydrogen or C 1-4 alkyl; R 7 represents hydrogen or C 1-4 alkyl; R 6 and R 7 together are a divalent radical of the general formula —N═CH— (i), —CH═N— (ii), —CH═CH— (iii), —CH 2 —CH 2 (iv) Can form Wherein one hydrogen atom in radicals (i) and (ii) may be substituted by C 1-4 alkyl radicals and one or more hydrogen atoms in radicals (iii) and (iv) are C 1-4 alkyl radicals May be substituted by; D represents a trisubstituted tetrahydrofuran derivative. The invention also relates to a process for the preparation of said compounds, to compositions containing said compounds and to their use as medicaments.
公开号:KR20010042852A
申请号:KR1020007011624
申请日:1999-05-06
公开日:2001-05-25
发明作者:메르포엘리벤；백스레오야코부스요제프；반데르베켄루이스요제프엘리자베쓰；오즈프랭크크리스토퍼；헤레스얀
申请人:디르크 반테；얀센 파마슈티카 엔.브이.；
IPC主号:

专利说明:

Water soluble azoles as broad-spectrum antifungals
Systemic fungal infections in humans are relatively rare in warm countries, and the vast majority of fungi that can become pathogenic usually live symbioticly in the body or are common in the environment. The incidence of a number of life-threatening systemic fungal infections has increased worldwide over the last few decades, and they are now seen as a major threat to many susceptible patients, especially those already in hospital. Most of the increase can be attributed to increased survival in patients with immune defenses and chronic use of antimicrobial agents. Moreover, the typical flora of many common fungal infections is also changing, thus increasing the importance of epidemiological approaches. Patients at greatest risk appear directly as a result of immunosuppression or HIV infection with cytotoxic drugs, or in other debilitating diseases such as cancer, acute leukemia, invasive surgical techniques or long-term exposure to antimicrobial agents. Include patients with impaired secondary immune function. The most common systemic fungal infections in humans are candidiasis, aspergillosis, histoplasmosis, coccidiosis, paracoccidiosis, blastomycesosis and cryptococcus.
Antifungal agents, such as ketoconazole, itraconazole and fluconazole, have been used to treat and prevent pre-systemic fungal infections in patients with immune defenses. However, there is a growing interest in some of these agents, in particular fungal resistance to agents having a relatively narrow spectrum, for example fluconazole. To make matters worse, about 40% of people with severe systemic fungal infections are recognized by the medical community as having little or no medicament available through oral administration. This inability is due to the fact that the patients are in a coma or suffer from severe gastric palsy. Thus, the use of insoluble or poorly soluble fungicides such as itraconazole, which is difficult to administer intravenously, is greatly hindered in patients in this group.
Onychomycosis may also be treated with an effective water soluble antifungal agent. The treatment of nail fungus by a transungual route has long been required. The problem raised here is that the antifungal agents must penetrate into and under the nail. Mertin and Lippold [J. Pharm. Pharmacol. (1997), 49, 30-34, noted that attention should be paid primarily to the water solubility of the compounds in order to select agents for topical application to the nail plate. Maximum flow through the nail is advantageously affected by increasing the water solubility of the antifungal agent. Of course, the effect of treating nail fungus by the route through the nail also depends on the efficacy of the antifungal agent.
As a result, there is a need for new antifungal agents, preferably broad-spectrum antifungal agents, which have no existing resistance and can be administered intravenously or via nails. Preferably, the antifungal agent should also be available in a pharmaceutical composition suitable for oral administration. This allows the doctor to recover from the condition requiring administration of the drug intravenously or through the nail and then continue treatment with the same drug.
US-4,267,179 contains (4-phenylpiperazin-1-yl-aryloxy-methyl-1,3-dioxolan-2-yl) -methyl-1H-imidazole and 1H-1,2,4- useful as antifungal agents. Heterocyclic derivatives of triazoles are disclosed. The patent includes itraconazole available worldwide as broad-spectrum antifungal agents. WO 93/19061 discloses [2R- [2α, 4α, 4 (R ^* )]], [2R- [2α, 4α, 4 (S ^* )]], [2S- [2α, 4α, 4 (S) of itraconazole. ^* )]] And [2S- [2α, 4α, 4 (R ^* )]] stereospecific isomers are disclosed, which are described to have greater solubility in water than their respective diastereomeric mixtures. WO 95/19983 describes [[4- [4- (4-phenyl-1-piperazinyl) phenoxy-methyl] -1,3- structurally related to some compounds of the invention and described as water-soluble antimicrobial agents. Derivatives of dioxolan-2-yl] methyl] -1H-imidazole and 1H-1,2,4-triazole are disclosed. WO 95/17407, WO 96/38443 and WO 97/00255 disclose tetrahydrofuran antifungal agents. The latter two publications disclose tetrahydrofuran antifungal agents which contain substituted groups that can be dissolved and / or suspended in an aqueous medium suitable for intravenous administration and can be readily converted into hydroxy groups in vivo. have. Saksena et al. Describe some tetrahydrofuran based azole antifungal agents in Bioorganic & Medicinal Chemistry Letters (1995), 5 (2), 127-132, for example (3R-cis) -4- [4. -[4- [4-[[5- (2,4-difluorophenyl) tetrahydro-5- (1H-1,2,4-triazol-1-ylmethyl) -3-furanyl] meth Oxy] phenyl] -1-piperazinyl] phenyl] -2- [2- (dimethylamino) ethyl] -2,4-dihydro-3H-1,2,4-triazol-3-one; have. Saeksana et al. Reported that the azole was much less active as an antifungal agent than SCH 51048.
The present invention relates to water-soluble azoles as broad-spectrum antifungal agents and methods for their preparation; The invention also relates to compositions containing them and their use as medicaments.
Unexpectedly, the compounds of the present invention are effective broad-spectrum antifungal agents with good water solubility.
The present invention relates to compounds of the general formula (I), N-oxide forms thereof, pharmaceutically acceptable addition salts and stereochemical isomers:

Where
L is the following general formula

Represents the radical,
From here,
Each Alk independently represents C _1-6 alkanediyl optionally substituted by hydroxy or C _1-4 alkyloxy;
Each n is independently 1, 2 or 3;
Y represents O, S or NR ² ;
Each R ¹ is independently hydrogen, aryl, Het ¹ , or halo, hydroxy, mercapto, C _1-4 alkyloxy, C _1-4 alkylthio, aryloxy, arylthio, arylC _1-4 alkyloxy, ArylC _1-4 alkylthio, cyano, amino, mono- or di (C _1-4 alkyl) amino, mono- or di (aryl) amino, mono- or di (arylC _1-4 alkyl) amino, C _1-4 alkyloxycarbonyl, amino, benzyloxycarbonyl, amino, aminocarbonyl, carboxyl, C _1-4 alkyloxycarbonyl, guanidyl pyridinyl, aryl, and each of the one selected independently from the group consisting of Het ^2, two or C _1-6 alkyl optionally substituted by three substituents;
Each R ² independently represents hydrogen or C _1-6 alkyl;
When R ¹ and R ² are bonded to the same nitrogen atom, they can together form a heterocyclic radical selected from the group consisting of morpholinyl, pyrrolidinyl, piperidinyl, homopiperidinyl and piperazinyl There is; These heterocyclic radicals are optionally C _1-4 alkyl, aryl, Het ² , arylC _1-4 alkyl, Het ² C _1-4 alkyl, hydroxyC _1-4 alkyl, amino, mono- or di (C _{1 -4} alkyl) amino, aminoC _1-4 alkyl, mono- or di (C _1-4 alkyl) aminoC _1-4 alkyl, carboxyl, aminocarbonyl, C _1-4 alkyloxycarbonyl, C _1-4 Or may be substituted by alkyloxycarbonylamino or mono- or di (C _1-4 alkyl) aminocarbonyl; Together they can form azido radicals;
Each R ³ independently represents hydrogen, hydroxy or C _1-4 alkyloxy;
Aryl represents phenyl, naphthalenyl, 1,2,3,4-tetrahydro-naphthalenyl, indenyl or indanyl; Each of these aryl groups is halo, C _1-4 alkyl, hydroxy, C _1-4 alkyloxy, nitro, amino, trifluoromethyl, hydroxyC _1-4 alkyl, C _1-4 alkyloxyC _1-4 Optionally substituted by one or more substituents selected from the group consisting of alkyl, aminoC _1-4 alkyl and mono- or di (C _1-4 alkyl) aminoC _1-4 alkyl;
Het ¹ represents monocyclic or bicyclic heterocyclic radicals wherein the monocyclic heterocyclic radicals are pyridinyl, piperidinyl, homopiperidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, Triazinyl, triazolyl, pyranyl, tetrahydropyranyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, thiazolyl, thiazolidinyl, isothiazolyl, Oxazolyl, oxazolidinyl, isoxazolyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, furanyl, tetrahydrofuranyl, thienyl, thiolyl and dioxolanyl; Bicyclic heterocyclic radicals include quinolinyl, 1,2,3,4-tetrahydro-quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, cinnaolinyl, chromanyl , Thiochromenyl, 2H-chromenyl, 1,4-benzodioxanyl, indolyl, isoindolyl, indolinyl, indazolyl, furinyl, pyrrolopyridinyl, furanopyridinyl, thienopyridinyl, Benzothiazolyl, benzoxazolyl, benzoisothiazolyl, benzisoxazolyl, benzimidazolyl, benzofuranyl and benzothienyl; The mono- or bicyclic heterocycle may each optionally be halo, C _1-4 alkyl, hydroxy, C _1-4 alkyloxy, nitro, amino, trifluoromethyl, hydroxyC _1-4 alkyl, C _{1- 4} alkyloxy-C _1-4 alkyl, aminoC _1-4 alkyl, mono- or di (C _1-4 alkyl) aminoC _1-4 alkyl, one selected from the group consisting of aryl and arylC _1-4 alkyl, Or if possible, substituted by more substituents;
Het ² is the same as Het ¹ and may also be a monocyclic heterocycle selected from the group consisting of piperazinyl, homopiperazinyl, 1,4-dioxanyl, morpholinyl and thiomorpholinyl; Wherein the monocyclic heterocycles are each optionally optionally halo, C _1-4 alkyl, hydroxy, C _1-4 alkyloxy, nitro, amino, trifluoromethyl, hydroxyC _1-4 alkyl, C _1-4 alkyl oxy-C _1-4 alkyl, amino C _1-4 alkyl, mono- or di-one selected from (C _1-4 alkyl) amino C _1-4 alkyl, aryl and aryl C _1-4 group consisting of alkyl, or where possible May be substituted by more substituents;
R ⁶ represents hydrogen or C _1-4 alkyl;
R ⁷ represents hydrogen or C _1-4 alkyl;
R ⁶ and R ⁷ together form a divalent radical of the formula -R ⁶ -R ^7- ,
Where -R ⁶ -R ⁷ -is
-N = CH- (i),
-CH = N- (ii),
-CH = CH- (iii),
-CH ₂ -CH ₂ (iv),
Wherein one hydrogen atom in radicals (i) and (ii) may be substituted by C _1-4 alkyl radicals, and one or more hydrogen atoms in radicals (iii) and (iv) are C _1-4 alkyl radicals May be substituted by;
D is the following general formula

Represents the radical,
From here,
X is N or CH,
R ⁴ is hydrogen or halo;
R ⁵ is halo.
As used above and below, halo means fluoro, chloro, bromo and iodo; C _1-4 alkyl includes straight and branched chain saturated hydrocarbon radicals having 1 to 4 carbon atoms such as methyl, ethyl, propyl, butyl and the like; C _1-6 alkyl includes straight and branched chain saturated hydrocarbons as defined in C _1-4 alkyl and their higher homologues containing 5 or 6 carbon atoms, for example pentyl or hexyl; C _1-6 alkanediyl is a straight and branched chain saturated divalent hydrocarbon radical having 1 to 6 carbon atoms such as methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl, 1,2-propanediyl, 1,2-butanediyl, 2,3-butanediyl and the like.
Pharmaceutically acceptable addition salts as mentioned above include the therapeutically active non-toxic acid addition salt forms which compounds of formula (I) can form. The latter can be used in the form of a base with a suitable acid, for example inorganic acid such as hydrochloric acid such as hydrochloric acid, hydrobromic acid and the like; Sulfuric acid; nitric acid; Phosphoric acid and the like; Or organic acids, such as acetic acid, propanoic acid, hydroxyacetic acid, 2-hydroxypropanoic acid, 2-oxopropanoic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, 2-hydroxy-1 Such as 2,3-propanetricarboxylic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, cyclohexanesulfonic acid, 2-hydroxybenzoic acid and 4-amino-2-hydroxybenzoic acid Treatment with acid can be conveniently obtained. Conversely, the salt form can be converted to the free base form by treatment with alkali.
Compounds of formula (I) containing acidic protons can be converted to their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Suitable base salt forms are, for example, ammonium salts, alkali metal salts and alkaline earth metal salts, for example lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases such as benzatin, N-methyl-D -Glucamine, 2-amino-2- (hydroxymethyl) -1,3-propanediol, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. Conversely, the salt form can be converted to the free acid form by treatment with an acid.
The term addition salts also includes hydrate and solvent addition salt forms which the compounds of general formula (I) can form. Examples of such forms are, for example, hydrates, alcoholates and the like.
The term "stereoisomer" as used above means all possible stereoisomeric forms in which the compound of formula (I) is present and therefore also includes all enantiomers, enantiomer mixtures and diastereomer mixtures. Unless otherwise stated or indicated, the chemical designation of a compound represents a mixture of all possible stereoisomers, which mixture includes all diastereomers and enantiomers of the basic molecular structure. The same applies to the intermediates referred to herein, which are used to prepare the final product of general formula (I).
By pure stereoisomers of the compounds and intermediates referred to herein are meant isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure of said compound or intermediate. In particular, the term `` stereoisomerically '' equivalent to `` chirally pure '' is at least 80% stereoisomeric excess (ie at least 90% of one isomer and up to 10% of the other possible isomers). Compounds or intermediates having from 1 to 100% excess of stereoisomers (ie, one isomer is 100% and none at all), more particularly from 90 to 100% stereoisomer, even more particularly 94 to 100% of stereoisomers and most In particular it relates to a compound or intermediate having a stereoisomeric excess of 97 to 100%. The terms 'enantiomerically pure' and 'diastereomerically pure' should be understood in a similar manner, but mean enantiomeric and diastereomeric excess of the respective mixtures.
As used herein, the terms cis and trans are used according to the Chemical Abstracts (CA) nomenclature and refer to dioxolane cyclic substituent positions in the ring moiety, more particularly in compounds of formula (I). For example, when setting the cis or trans configuration of a dioxolane ring in the radical of the general formula (D ₁ ), a substituent having the highest priority on the carbon atom at the 2 position of the dioxolane ring, and dioxane Substituents with the highest priority on the carbon atom at position 4 of the solan ring are considered (priority of substituents is determined according to the Cahn-Ingold-Prelog sequence rule). When the two substituents with the highest priority are on the same side of the ring, the coordination is labeled cis, otherwise the coordination is labeled trans.
Compounds of general formula (I) contain at least two asymmetric centers, all of which may have an R- or S-configuration. As used herein, stereochemical descriptors representing stereochemical configuration of each of two or more asymmetric centers also conform to CA nomenclature. For example, compound 86, ie [2S- [2α, 4α [(R ^* , S ^* ) (S ^* )]]]-4- [4- [4- [4-[[2- (2,4 -Difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] Absolute of asymmetric carbon atoms of phenyl] -2,4-dihydro-2- [2-[(1-phenylethyl) amino] -1-methylpropyl] -3H-1,2,4-triazol-3-one Coordination is shown below. In this compound the dioxolane ring is in cis configuration:

The ring numbering of the dioxolane ring according to the CA nomenclature is represented by the radicals D ₁ and D ₂ below:

Absolute stereochemical coordination has not been determined experimentally for the compounds of formula (I) and some of the intermediates used for their preparation. In this case, the separated stereoisomeric form is first labeled "A", the second is labeled "B", and if there are more stereogenic forms, the third is "C" and the fourth is "D", etc., and no further mention is made of the actual stereochemical configuration. However, the stereogenic form represented by "A", "B", "C", "D" and the like can be clearly specified. For example, where "A" and "B" have enantiomeric relationships, they can be clearly specified by their optical rotation. One skilled in the art can determine the absolute configuration of such compounds using methods known in the art such as, for example, X-ray diffraction. If "A" and "B" are stereoisomeric mixtures, they may be further separated, wherein each separated first fraction is labeled "A1" and "B1" and the second separated fraction is labeled "A2" and " B2 ", and no substantial stereochemical configuration is mentioned.
The N-oxide form of the compound means that the compound comprises a compound of formula (I) in which one or several nitrogen atoms are oxidized to so-called N-oxides.
Whenever used hereafter, the term “compound of formula (I)” is also intended to include their N-oxide forms, their pharmaceutically acceptable addition salts, and their stereochemical isomers.
Within the scope of the present invention, R ⁶ and R ⁷ are each independently suitably hydrogen or methyl; Together, they form -R ⁶ -R ⁷ -which is a radical of the general formulas (i) to (iv), optionally substituted by C _1-4 alkyl.
D is suitably a radical of the general formula D ₁ .
X is suitably N.
R ² is suitably hydrogen, methyl or ethyl.
R ⁴ and R ⁵ are suitably the same and are preferably chloro or fluoro. In particular, both R ⁴ and R ⁵ are fluoro.
Aryl suitably represents phenyl, 1,2,3,4-tetrahydro-naphthalenyl, naphthalenyl or indanyl, where aryl is halo, C _1-4 alkyloxy, hydroxyC _1-4 At least one substituent selected from the group consisting of alkyl, C _1-4 alkyloxyC _1-4 alkyl, hydroxy, aminoC _1-4 alkyl and mono- or di (C _1-4 alkyl) aminoC _1-4 alkyl Optionally substituted.
Het ¹ is suitably monocyclic heterocyclic radical, preferably pyridinyl, piperidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxa Zolyl, isoxazolyl, pyrrolyl, furanyl, tetrahydrofuranyl or thienyl, more preferably pyridinyl, piperidinyl or tetrahydrofuranyl, and these monocyclic heterocycles are optionally halo, C _{1- 4} alkyl, hydroxy, C _1-4 alkyloxy, nitro, amino, trifluoromethyl, hydroxyC _1-4 alkyl, C _1-4 alkyloxy-C _1-4 alkyl, aminoC _1-4 alkyl and It may be optionally substituted by one selected from the group consisting of mono- or di (C _1-4 alkyl) amino-C _1-4 alkyl, or possibly more substituents.
Het ¹ may also suitably be chromanyl.
A group of compounds of interest within the present invention are compounds of general formula (I), in which L represents a radical of general formula (a), (b) or (c), in particular of general formula (a).
Another interesting group is Alk C _1-6 alkanediyl; Especially 1,2-ethanediyl, 1,2-propanediyl, 2,3-propanediyl, 1,2-butanediyl, 3,4-butanediyl, 2,3-butanediyl, 2,3-pentanediyl and 3,4-pentanediyl; In particular 2,3-butanediyl.
Another interesting group is that R ¹ is hydrogen, aryl, Het ¹ , or halo, hydroxy, C _1-4 alkyloxy, aryloxy, arylC _1-4 alkyloxy, cyano, amino, mono- or di (C _{Consisting of 1-4} alkyl) amino, mono- or di (arylC _1-4 alkyl) amino, C _1-4 alkyloxycarbonylamino, C _1-4 alkyloxycarbonyl, aminocarbonyl, aryl and Het ² C _1-6 alkyl optionally substituted by one, two or three substituents each independently selected from the group;
R ² represents hydrogen or C _1-6 alkyl;
When R ¹ and R ² are bonded to the same nitrogen atom, they may together form a heterocyclic radical selected from the group consisting of morpholinyl, pyrrolidinyl, piperidinyl and piperazinyl; These heterocyclic radicals are optionally C _1-4 alkyl, aryl, arylC _1-4 alkyl, hydroxyC _1-4 alkyl, amino, mono- or di (C _1-4 alkyl) amino, mono- or di ( C _1-4 alkyl) aminoC _1-4 alkyl or C _1-4 alkyloxycarbonylamino; These together include a compound of formula (I) capable of forming azido radicals.
Particular compounds are those in which R ⁶ and R ⁷ together form -R ⁶ -R ^7- , which is a radical of formula (ii) or (iii), wherein D is a radical of formula D ₁ or D ₂ , wherein R ⁴ And R ⁵ are all chloro or fluoro and X is N); More particularly, the dioxolane ring is a compound of formula (I) wherein the ring is a radical of formula D ₁ or D ₂ having a cis configuration.
Other particular compounds include those in which L represents a radical of formula (a) wherein R ² is hydrogen, methyl or ethyl and R ¹ is hydrogen, aryl, Het ¹ , or hydroxy, C _1-4 alkyloxy, aryl Oxy, arylC _1-4 alkyloxy, cyano, amino, mono- or di (C _1-4 alkyl) amino, mono- or di (arylC _1-4 alkyl) amino, aminocarbonyl, C _1-4 C _1-6 alkyl optionally substituted by one, two or three substituents each independently selected from the group consisting of alkyloxycarbonyl, C _1-4 alkyloxycarbonylamino, aryl and Het ² ; R ¹ and R ² together with the nitrogen atom to which they are attached form morpholinyl, pyrrolidinyl, piperidinyl or pyrerazinyl, wherein the heterocyclic radical is C _1-4 alkyl, aryl, aryl C _1-4 alkyl, hydroxyC _1-4 alkyl, amino, mono- or di (C _1-4 alkyl) amino, mono- or di (C _1-4 alkyl) aminoC _1-4 alkyl or C _1-4 Optionally substituted by alkyloxy-carbonylamino; R ¹ and R ² together with the nitrogen atom to which they are attached are compounds of formula (I) which form azido radicals.
Another particular compound is that L represents a radical of formula (a), (e) or (f), in particular a radical of formula (a), wherein R ¹ is aryl, Het ¹ , or aryloxy, aryl Thio, arylC _1-4 alkyloxy, arylC _1-4 alkylthio, mono- or di (aryl) -amino, mono- or di (arylC _1-4 alkyl) amino, benzyloxycarbonylamino, aryl and C _1-6 alkyl substituted by at least one substituent selected from the group consisting of Het ² ; More particularly R ¹ is substituted by aryl or at least one substituent selected from the group consisting of aryloxy, arylC _1-4 alkyloxy, mono- or di (arylC _1-4 alkyl) amino, aryl and Het ² A compound of formula (I) representing C _1-6 alkyl.
Preferred compound groups are those in which R ⁶ and R ⁷ together form -R ⁶ -R ^7- , which is the radical of formula (ii) or (iii); D is a radical of formula D ₁ or D ₂ , wherein R ⁴ and R ⁵ are both fluoro and X is N; L represents a radical of formula (a), where R ² is hydrogen or methyl, R ¹ is hydrogen, aryl, Het ¹ , or hydroxy, C _1-4 alkyloxy, aryloxy, arylC _{1- 4} alkyloxy, cyano, amino, mono- or di (C _1-4 alkyl) amino, mono- or di (arylC _1-4 alkyl) amino, aminocarbonyl, C _1-4 alkyloxycarbonyl, C C _1-6 alkyl optionally substituted by one, two or three substituents each independently selected from the group consisting of _1-4 alkyloxycarbonylamino, aryl and Het ² ; R ¹ and R ² together with the nitrogen atom to which they are attached form morpholinyl, pyrrolidinyl, piperidinyl or piperazinyl; Wherein the heterocyclic radical is C _1-4 alkyl, aryl, arylC _1-4 alkyl, hydroxyC _1-4 alkyl, amino, mono- or di (C _1-4 alkyl) amino, mono- or di (C _1-4 alkyl) aminoC _1-4 alkyl or C _1-4 alkyloxycarbonylamino, including compounds of the general formula (I) which may be optionally substituted.
Another preferred group of compounds is a compound of formula (I) wherein R ⁶ and R ⁷ are other than hydrogen, which group is represented by a compound of formula (I ').
Particularly preferred groups of compounds include compounds of formula (I), wherein L is a radical of the formula:

Where
Alk is as defined above, but preferably 1,2-ethanediyl, 1,2-propanediyl, 2,3-propanediyl, 1,2-butanediyl, 3,4-butanediyl, 2,3- Butanediyl, 2,3-pentanediyl or 3,4-pentanediyl;
Z ¹ is aryl, arylmethyl, arylethyl, Het ¹ or C _1-4 alkyl, preferably optionally substituted phenyl or optionally substituted phenylmethyl, isopropyl or t-butyl;
Z ² is methyl, preferably hydrogen, methyl optionally substituted by hydrogen, carboxyl, C _1-4 alkyloxycarbonyl, aminocarbonyl, or hydroxy, methoxy, amino or mono- or di (methyl) amino Or hydroxymethyl;
Z ¹ and Z ² together with the carbon atom to which they are attached form a piperidinyl ring substituted by arylmethyl, arylethyl or C _1-4 alkyl;
Z ³ is O, NC _1-4 alkyl or N-aryl.
Most preferred compounds are as follows:
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(1-phenylethyl) amino] -1-methylpropyl]- 3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(2-phenylethyl) amino] -1-methylpropyl]- 3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2- (4-phenyl-1-piperazinyl) -1-methylpropyl ] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(3-phenylpropyl) amino] -1-methylpropyl]- 3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2- [2-[[(2-fluorophenyl) methyl] amino] -1-methylpropyl] -2,4 -Dihydro-3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(phenylmethyl) amino] -1-methylpropyl] -3H- 1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[[(2-methoxyphenyl) methyl] amino] -1- Methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(2-phenoxyethyl) amino] -1-methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(2,3-dihydro-1H-inden-2-yl ) Amino] -1-methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2- [2-[[1- (4-fluorophenyl) ethyl] amino] -1-methylpropyl] -2 , 4-dihydro-3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[[1- (phenylmethyl) -4-piperidinyl] amino ] -1-methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2- (4-morpholinyl) -1-methylpropyl] -3H- 1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[[1- (hydroxymethyl) -2-phenylethyl] amino ] -1-methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(2-hydroxy-1-phenylethyl) amino] -1 -Methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(2-hydroxy-2-phenylethyl) amino] -1 -Methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[[1- (hydroxymethyl) -2-methylpropyl] amino ] -1-methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(1-phenylethyl) amino] -1-methylpropyl]- 3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [1- (1-phenylethyl) -4-piperidinyl] -3H- 1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-dichlorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolane -4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[[1- (hydroxymethyl) -2-methylpropyl] amino]- 1-methylpropyl] -3H-1,2,4-triazol-3-one;
2- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-4- [2-[(phenylmethyl) amino] -1-methylpropyl] -3H- 1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [4-[(phenylmethyl) amino] cyclohexyl] -3H-1,2 , 4-triazol-3-one;
N-oxides, pharmaceutically acceptable addition salts and stereochemical isomers thereof.
Stereochemically pure most preferred compounds
[2S- [2α, 4α [(R ^* , S ^* ) (S ^* )]]]-4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2 -(1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-di Hydro-2- [2-[(1-phenylethyl) amino] -1-methylpropyl] -3H-1,2,4-triazol-3-one;
[2S- [2α, 4α (S ^* , R ^* )]]-4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1, 2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2 -[(Phenylmethyl) amino] -1-methylpropyl] -3H-1,2,4-triazol-3-one and
[2S- [2α, 4α [(R ^* , S ^* ) (R ^* )]]]-4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2 -(1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-di Hydro-2- [2-[[1- (hydroxymethyl) -2-methylpropyl] amino-1-methylpropyl] -3H-1,2,4-triazol-3-one.
Compounds of the invention wherein R ⁶ and R ⁷ are other than hydrogen, and R ⁶ and R ⁷ are represented by R ^{6 '} and R ^7' , which are represented by the general formula (I '), Intermediate of II), wherein W ¹ is a suitable leaving group such as halogen (eg iodo), arylsulfonyloxy or alkanesulfonyloxy group (eg p-toluenesulfonyloxy, naphthylsulfonyloxy Or methanesulfonyloxy)) in a reaction-inert solvent such as N, N-dimethylformamide, N, N-dimethyl-acetamide, 1-methyl-2-pyrrolidinone, 1,3-dimethyl- It can be prepared by reacting with an intermediate of formula (III) in the presence of a suitable base such as sodium hydroxide or sodium hydride in 2-imidazolidinone, sulfolane and the like:

In the above and subsequent preparations, the reaction product can be separated from the reaction medium and further purified as necessary, for example according to methods generally known in the art such as extraction, crystallization, polishing and chromatography. In particular, stereoisomers can be chromatographically separated using a chiral stationary phase such as Chiralpak AD (amylose 3,5-dimethylphenyl carbamate) or Chiralpak AS purchased from Daicel Chemical Industries, Ltd. of Japan.
Compounds of formula (I ') also contain intermediates of formula (IV), for example intermediates of formula (V) in the presence of a base such as potassium hydroxide in a reaction-inert solvent such as dimethylsulfoxide (Wherein W ² is a suitable leaving group, for example halogen, and reactive amino groups at L, for example primary and secondary amines, if present are protecting groups P, for example C _1-4 Protected with alkyloxycarbonyl groups). When L is protected, deprotection techniques known in the art can be used to obtain compounds of general formula (I ′) after the N-alkylation reaction.

A compound of formula (I '), wherein L is a radical of formula (a), which compound is represented by formula (I'-a), is an intermediate of formula (VI), wherein W ³ is an example. For example halogen, arylsulfonyloxy or alkanesulfonyloxy groups (e.g. p-toluenesulfonyloxy, naphthylsulfonyloxy or methanesulfonyloxy) are optionally selected from suitable bases such as sodium carbonate or potassium carbonate, tri In the presence of ethylamine and the like, optionally, a reaction-inert solvent such as N, N-dimethylformamide, N, N-dimethyl-acetamide, 1-methyl-2-pyrrolidinone, 1,3-dimethyl-2 It can be prepared by reacting with an intermediate of formula (VII) in imidazolidinone, sulfolane and the like. When R ¹ and R ² together with the nitrogen atom to which they are attached form azido radicals, NaN ₃ may be used as intermediate of formula (VII):

A compound of formula (I) wherein at least one of R ⁶ and R ⁷ is hydrogen and R ⁶ and R ⁷ are represented by R ^{6 ″} and R ^{7 ″} (this compound is represented by formula (I ″)) Can be prepared according to the reaction procedure of Scheme 1:
Scheme 1

In Scheme 1, an intermediate of formula (VIII-a), wherein NP ₂ is a protected amino group, where P is for example a C _1-4 alkyloxycarbonyl group, or for example a nitro group Functional derivatives of NP ₂ ) are reacted with intermediates of formula (II) according to the methods described for the preparation of compounds of formula (I ′). The intermediates of formula (VIII-b) thus obtained can be deprotected according to deprotection techniques known in the art, thereby obtaining amine derivatives of formula (VIII-c). When NP ₂ is a nitro group, reduction techniques known in the art can be used to obtain amines of general formula (VIII-c). The amine derivative of formula (VIII-c) can then be reacted with phenyl chloroformate or a functional derivative thereof. To obtain a compound of formula (I ″) wherein R ^{6 ″} is C _1-4 alkyl, the amine derivative of formula (VIII-c) is first substituted with C _1-4 alkyl-W ⁴ where W ⁴ is suitable After reacting with a leaving group, such as halogen), followed by reaction with phenyl chloroformate. The intermediate of general formula (VIII-e) obtained can be reacted with the intermediate of general formula (IX), wherein reactive amino groups such as primary and secondary amines in L, if present, for example C ₁ Protected with a protecting group P such as the _-4 alkyloxycarbonyl group. Then, suitably, the reactive amino group can be deprotected using deprotection techniques known in the art to obtain the compound of the general formula (I ″).
Compounds of formula (I) may also be interconverted according to transformation techniques known in the art.
For example, a compound of formula (I '), wherein L is a radical of formula (b), which compound is represented by formula (I'-b), is an acylation method known in the art, for example For example, it may be prepared using the method described in "Principles of Peptide Synthesis", M. Bodanszky, Springer-Verlag Berlin Heidelberg, 1984.
Certain acylation methods involve compounds of the general formula (I'-a) wherein R ¹ is hydrogen, which compound is represented by the general formula (I'-a-1), such as sodium bicarbonate or N, Intermediates of formula (Xb) in the presence of N-dimethylaminopyridine or functional derivatives thereof, such as dichloromethane, dichloroethane, tetrahydrofuran and the like, wherein W ⁵ is for example halogen Or a suitable leaving group such as a hydroxy group).

When W ⁵ is hydroxy, for example, by adding a diimide such as N, N-dicyclohexylcarbodiimide, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide or a functional derivative thereof It may be convenient to activate the carboxylic acid of formula (Xb). Alternatively, carbonyldiimidazole or a functional derivative thereof may be added to activate the carboxylic acid of formula (Xb).
When using chirally pure intermediates of formula (Xb), hydroxybenzotriazole, benzotriazolyloxytris (dimethylamino) phosphonium hexafluorophosphate, tetrapyrrolidinophosphonium hexafluorophosphate, bromine Motripyrrolidinophosphonium hexafluorophosphate or functional derivatives thereof can be added to perform fast and enantiomerization-free coupling (see D. Hudson, J. Org. Chem., 1988, 53, p617). & 1999 Novabiochem catalog & peptide Synthesis Handbook).
Compounds of formula (I ') wherein L is a radical of formula (c), wherein acylation processes similar to those for preparing compounds of formula (I'-b) are formula (I'-c) It can be used to manufacture). In this analogous process, the intermediate of formula (Xb) is a carbonate of formula C _1-4 alkyl-OC (= O) -OR ¹ (Xc-1), formula Cl-C (= 0) -OR ¹ Chloromate of (Xc-2) or C _1-4 alkyl-OC (═O) —OC (═O) —OC _1-4 alkyl (Xc-3).
Compounds of formula (I ') wherein L is a radical of formula (d), wherein acylation processes similar to those for preparing compounds of formula (I'-b) are formula (I'-d) It can be used to manufacture). In this analogous reaction process, the intermediate of formula (Xb) is an isocyanate of formula O = C = NR ¹ (Xd-1), isothiocyanate of formula S = C = NR ¹ (Xd-2), general Phenylcarbamate of the formula Phenyl-OC (= O) -NR ¹ R ² (Xd-3), Phenylthiocarbamate of the general formula phenyl-OC (= S) -NR ¹ R ² (Xd-4) or general formula Replaced by an intermediate of C _1-4 alkyl-SC (═NR ² ) —NR ¹ R ² (Xd-5).
A compound represented by the general formula (I'-a-1) also in a ketone or aldehyde (here represented by the general formula ^{R 1a C (= O) -R} 1b (XI), R 1a and R ^1b is a radical -CHR ^1a R ^1b Reductively N-alkylated with a definition of R ¹ to form a compound of formula (I'-a-2). The reductive N-alkylation is carried out in a reaction-inert solvent such as toluene, methanol, tetrahydrofuran or mixtures thereof, for example reducing borohydrides such as sodium borohydride, zinc borohydride, lithium borohydride, sodium Cyanoborohydride or triacetoxy borohydride). When boron hydride is used as the reducing agent, J. Org. It may be convenient to use a catalyst as described in Chem, 1990, 55, 2552-2554, for example titanium (IV) isopropoxide. It may also be convenient to use hydrogen as a reducing agent in combination with a suitable catalyst, for example palladium on charcoal or platinum on charcoal. A suitable reagent such as, for example, aluminum t-butoxide, calcium oxide, calcium hydride or titanium (IV) alkoxide, for example titanium (IV) isopropoxide or titanium (IV) -n-butoxide, is added to the reaction mixture. It can be added to enhance the formation of Schiff base in the first step of reductive N-alkylation. In order to prevent undesirably further hydrogenation of certain functional groups in the reactants and reaction products, a suitable catalyst-poison such as thiophene, butanethiol or quinoline-sulfur is also added to the reaction mixture. Can be added. Agitation and optionally elevated temperatures and / or pressures may improve the reaction rate.

Wherein L is a radical of formula (a) and R ¹ is a -CH ₂ -CH (OH) substituent wherein the substituent belongs to a substituent group of C _1-6 alkyl in the definition of R ¹ Compounds of '), which are represented by general formula (I'-a-3), are prepared by reacting intermediates of general formula (I'-a-1) in a reaction-inert solvent such as 2-propanol It can be prepared by reacting with the epoxide of (XII).

Compounds of formula (I) containing a C _1-4 alkyloxycarbonylamino moiety are correspondingly employed using techniques known in the art, such as, for example, in dichloromethane in the presence of trifluoroacetic acid. It can be converted into the compound of general formula (I) containing an amino moiety.
Compounds of general formula (I ′) containing primary amines first protect the primary amine with an appropriate protecting group such as, for example, an arylalkyl group such as benzyl, followed by, for example, paraformaldehyde. Mono-methylation can be accomplished by methylation of the secondary amine using methylation techniques known in the art such as by reaction. The tertiary amine thus obtained is de-protected by reaction with hydrogen in tetrahydrofuran or methanol in the presence of a catalyst such as, for example, palladium on charcoal, using deprotection techniques known in the art. Can be obtained.
Compounds of formula (I) may also be converted to the corresponding N-oxide form according to methods known in the art for converting trivalent nitrogen to its N-oxide form. The N-oxidation reaction can generally be carried out by reacting the starting material of general formula (I) with an appropriate organic or inorganic peroxide. Suitable inorganic peroxides are, for example, hydrogen peroxide, alkali metal or alkaline earth metal peroxides such as sodium peroxide, potassium peroxide; Suitable organic peroxides are peroxy acids, for example benzene carboperoxo acids or halosubstituted benzene carboperoxo acids, for example 3-chlorobenzenecarboperoxo acid, peroxoalkanoic acid, for example peroxoacetic acid, alkyl Hydroperoxides such as t-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols such as ethanol, hydrocarbons such as toluene, ketones such as 2-butanone, halogenated hydrocarbons such as dichloromethane, and mixtures of these solvents .
Some of the intermediates and starting materials used in this reaction method are commercially available or can be synthesized according to the methods described in other documents, for example US-4,791,111, US-4,931,444 and US-4,267,179. Some methods for preparing the intermediates of the present invention are described below.
For example, an intermediate of formula (III), wherein L is a radical of formula (a), which intermediate is represented by formula (III-a), represents a compound of formula (I'-a-1) Intermediates of formula (XIII) containing carbonyl, wherein Alk = O is substituted by an oxo group according to the same reaction method as described for reductive N-alkylation with an intermediate of formula (XI) Can be prepared by reductive amination with an intermediate of formula (VII).

The reaction process can be carried out from a chirally pure starting material using a stereoselective reaction process to obtain chirally pure intermediates of formula (III-a). For example, the stereoselective reductive amination of intermediates of general formula (XIII) in chiral pure form and of general formula (VII) in chiral pure form is the thiophene solution and titanium (IV) isopropoxide It can be a reaction using hydrogen on charcoal palladium as reducing agent in the presence of. The resulting stereoisomers can be separated using chromatography or other techniques known in the art.
It may also be convenient to carry out the reaction on alkylphenoxy derivatives of the intermediates of general formula (XIII).
Reduction techniques known in the art, such as reducing intermediates of formula (III-a), wherein R ¹ is an arylC _1-6 alkyl group, for example, with hydrogen in the presence of palladium on active charcoal Reduction to obtain an intermediate of formula (III-a) wherein R ¹ is hydrogen, which is represented by formula (III-a-1).

Intermediates of formula (III-a-1) are, for example, those described in "Priciples of Peptide Synthesis", M. Bodanszky, Springer-Verlag Berlin Heidelberg, 1984 and 1999 Novabiochem Catalog & Peptide Synthesis Handbook. Intermediates of formula (III), wherein L is a radical of formula (b), (c) or (d) using acylation methods known in the art, each of which is formula (III-b), (III) -c) and (III-d)).
In addition, the amide of formula (III-b) may be hydrogenated with an appropriate acid, for example hydrochloric acid, to obtain an intermediate of formula (III-a-1).
Pure stereoisomers of the compounds and intermediates of the invention can be obtained by applying methods known in the art. Diastereomers can be separated by selective crystallization and chromatography techniques, for example by physical separation methods such as liquid chromatography using chiral stationary phases. Enantiomers can be separated from one another by selectively crystallizing their diastereomeric salts with optically active acids. Alternatively, enantiomers can be separated by chromatography techniques using chiral stationary phases. The pure stereoisomers can also be derived from the corresponding pure stereoisomers of the appropriate starting materials, provided that the reaction occurs stereoselectively or stereospecifically. Preferably, for the purpose of specific stereoisomers, the compounds will be synthesized by stereoselective or stereospecific methods of preparation. These methods will advantageously utilize chirally pure starting materials. Stereoisomers of compounds of formula (I) are expressly included within the scope of this invention.
Chirally pure forms of the compounds of formula (I) form the preferred compound groups. Thus, the chirally pure forms of the intermediates of the general formulas (II), (III) and (VI), their N-oxide forms and their addition salt forms, in particular, give rise to chirally pure compounds of the general formula (I) It is useful for manufacturing. In addition, enantiomeric and diastereomer mixtures of intermediates of formulas (II), (III) and (VI) are useful for preparing compounds of formula (I) having the corresponding configuration. Chirally pure forms of the intermediates of general formula (III) and also mixtures of enantiomers and diastereomers are considered novel.
An intermediate of formula (III-a) wherein R ¹ and R ² are hydrogen and Alk is —CH (CH ₃ ) —CH (CH ₃ ) —, where the asymmetric carbons both have an S-configuration This intermediate is represented by formula (SS) (III-a-2)), or a specific method for stereoselectively preparing alkoxyphenyl analogs thereof is shown in Scheme 2a.
Scheme 2a

The reaction of the intermediate of formula (XIV) with (4R-trans) -4,5-dimethyl-2,2-dioxide-1,3,2-dioxathiolane is a suitable solvent, preferably a polar aprotic solvent. For example in the presence of a base such as potassium t-butanolate, potassium hydroxide or potassium hydride in dimethylacetamide or N, N-dimethylformamide. An acid, such as sulfuric acid, is then added to the reaction mixture to obtain an intermediate of formula (SR) (XV), wherein the 2-hydroxy-1-methylpropyl moiety has the erythro form. Thereafter, the carbon atoms with alcohol functional groups in the 2-hydroxy-1-methylpropyl moiety are epimerized (preferably 100% conversion) to give intermediate (SS) (XVII), wherein 2-amino-1-methyl The profile region has a threo form. Both paths are convenient.
The first route is common, for example, by derivatizing a hydroxy group with an organic acid, such as sulfonic acid (such as p-toluenesulfonic acid or methanesulfonic acid), thereby converting the alcohol functional group to the appropriate leaving group O-LG. Obtaining an intermediate of formula (SR) (XVI). The carbon atom having the leaving group in the intermediate (SR) (XVI) is then epimerized (preferably 100% conversion) by a suitable nucleophilic reagent such as NaN ₃ and S _N2 -type reaction and then reduced Primary amines of formula (SS) (XVII) can be obtained. Alternatively, Gabriel synthesis, its Ing-Manske modification or another functional modification can be used to prepare the primary amine of formula (SS) (XVII).
Another route for stereochemically converting carbon atoms with alcohol functional groups is to use the Mitsunobu reaction. The alcohol functional groups of the intermediate of formula (SR) (XV) are diisopropyl azodicarboxylate or functional derivatives thereof in a polar aprotic solvent, for example dimethylacetamide or dimethylformamide in the presence of triphenylphosphine. Activated with diethyl azodicarboxylate, for example. The activating alcohol thus obtained is then reacted with an amide such as 2,2,2-trifluoroacetamide or a functional derivative thereof. The amide obtained by converting the 2-hydroxy-1-methylpropyl moiety to the treo form can be hydrolyzed using hydrolysis techniques known in the art to obtain intermediates of formula (SS) (XVII).
Additional conversion steps can be introduced as shown in Scheme 2b to obtain intermediates of formula (SR) (XVII).
Scheme 2b

The intermediate of formula (SR) (XV) is converted to the intermediate of formula (SS) (XV) using two possible routes. The first involves converting the alcohol functional group into the appropriate leaving group O-LG as described above to obtain an intermediate of formula (SR) (XVI). The carbon atom having the leaving group in the intermediate (SR) (XVI) is then subjected to a suitable nucleophilic reagent such as an alcoholate such as benzyloxy group; Hydroxy salts of alkali metals such as sodium or potassium hydroxide; Epimerization (preferably 100% conversion) can be effected by S _N2 -type reactions with acetates such as sodium acetate. This reaction is carried out in a suitable solvent, preferably a polar aprotic solvent, for example dimethylacetamide, N-methylpyrrolidinone, dimethylimidazolidinone or sulfolane. If alcoholates or acetates are used in the S _N2 reaction, the obtained intermediates can be deprotected using deprotection techniques known in the art to afford alcohol intermediates of formula (SS) (XV).
Another route involves the Mitsunobu reaction. The alcohol functionality of the intermediate of formula (SR) (XV) is activated as described above. The activated alcohol thus obtained is then reacted with a carboxylic acid such as 4-nitrobenzoic acid, acetic acid, monochloroacetic acid. The obtained esters can be hydrolyzed using hydrolysis techniques known in the art to afford intermediates of formula (SS) (XV).
The intermediate of formula (SS) (XV) is then reacted in the same reaction route as described for preparing intermediate (SS) (XVII) starting from (SR) (XV) of formula (SR) (XVII) Intermediates can be obtained.
Finally, the alkoxyphenyl moiety of the intermediate of formula (SS) (XVII) or (SR) (XVII) can be prepared using, for example, hydrobromic acid or a mixture of hydrobromic acid and hydrobromic acid in aceic acid in the presence of NaHSO ₃ . Conversion to phenol sites can yield intermediates of formula (SS) (III-a-2) or (SR) (III-a-2).
Suitable alternatives to (4R-trans) -4,5-dimethyl-2,2-dioxide-1,3,2-dioxathiolane include the following chirally pure intermediates:

Wherein LG is a leaving group such as, for example, p-toluenesulfonyl.
Intermediates of formula (III-a-2), wherein the 2-hydroxy-1-methylpropyl moiety has the form [R- (R ^* , R ^* )], which intermediate is (RR) (III-a-2) May be prepared using a reaction route as shown in Scheme 2, except that (4R-trans) -4,5-dimethyl-2,2-dioxide-1,3,2-dioxathiolane Is replaced by its enantiomer (4S-trans) -4,5-dimethyl-2,2-dioxide-1,3,2-dioxathiolane.
The intermediate of formula (VI) can be prepared by reducing the intermediate of formula (XIII) and then introducing the leaving group W ³ . In particular, intermediates of formula (VI) wherein Alk is -CH (CH ₃ ) -CH (CH ₃ )-, which intermediates are represented by formula (VI-a), are prepared according to the scheme shown in Scheme 3. Can be. Optionally a chiral of general formula (VI-a) represented by (SS) (VI-a), (SR) (VI-a), (RS) (VI-a) and (RR) (VI-a) Pure intermediates can be prepared using the following procedure.
Scheme 3

Suitable stereoselective reducing conditions include the use of K-selectride in a suitable solvent such as dimethylacetamide or tetrahydrofuran; Sodium borohydride, for example in combination with CeCl ₃ .7H ₂ O, ZnCl ₂ or CaCl ₂ .2H ₂ O, optionally in a suitable solvent such as dimethylacetamide, dimethylformamide, methanol or tetrahydrofuran. do. Such reducing conditions are advantageous for the threo form of the 2-hydroxy-1-methylpropyl moiety, ie a form in which two asymmetric carbon atoms have the same absolute configuration. Recrystallization of the intermediate of formula (XVIII) obtained after stereoselective reduction may even further improve the treo / erythro ratio, favoring the treo form. Subsequently, the desired stereoisomeric form of the intermediate of the general formula (XVIII), which is (RR) (XVIII), (SS) (XVIII), (RS) (XVIII) and (SR) (XVIII), is for example Japanese Daicel Chromatographic optionally separated using a chiral stationary phase such as Chiralpak AD (amylose 3,5 dimethylphenyl carbamate) purchased from Chemical Industries, Ltd. The intermediate of formula (XVIII) or one or more stereoisomers thereof may be further reacted with the intermediate of formula (II) as described above for the general preparation of compounds of formula (I ′). Finally, the obtained intermediate of the general formula (XIX) or a hydroxy group in its chiral pure form is derivatized by derivatization with an organic acid such as, for example, sulfonic acid (e.g. p-toluenesulfonic acid or methanesulfonic acid). Conversion to group W ³ can yield general formula (VI-a) or its chirally pure form.
Compounds of formula (I), pharmaceutically acceptable addition salts and stereochemical isomers thereof are useful agents for controlling fungi in vivo. Compounds of the invention are broad-spectrum antifungal agents. These include a wide variety of fungi, such as Candida spp., For example Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis ( Candida parapsilosis, Candida kefyr, Candida tropicalis; Aspergillus spp., For example Aspergillus fumigatus, Aspergillus niger, Aspergillus flavus; Cryptococcus neoformans; Sporotrix schenckii; Fonsecaea spp .; Epidermophyton floccosum; Microsporum canis; Trichophyton spp .; Fusarium spp .; And several dematiaceous hyphomycetes. Of particular interest is the improved activity of some compounds of the invention against Fusarium species.
In vitro experiments involving fungal susceptibility determinations of the compounds of the present invention as described in the pharmacological examples below show that the compounds of general formula (I) have inherent inhibitory capacity that is beneficial for fungal growth, for example, in Candida albicans. Indicates that Other in vitro experiments such as, for example, determining the effect of a compound of the present invention on sterol synthesis in Candida albicans also demonstrate their antifungal efficacy. In addition, in vivo experiments in several mouse, guinea-pig and rat models indicate that, after both oral and intravenous administration, the compounds of the present invention are potent antifungal agents.
A further advantage of some compounds of the present invention is that they are fungistatic, as are most known azole antifungal agents, but also fungicidal at acceptable therapeutic dosages for many fungal isolates.
The compounds of the present invention are chemically stable and have good oral availability.
The solubility profile for the aqueous solution of the compound of formula (I) makes this compound suitable for intravenous administration. Particularly interesting compounds are water-solubility of at least 0.1 mg / ml at a pH of at least 4, preferably at least 1 mg / ml of water-solubility at a pH of at least 4 and more preferably at least 5 mg / ml at a pH of at least 4. Compound of formula (I) having a water solubility of ml.
In light of the utility of the compounds of general formula (I), a method is provided for treating warm-blooded animals, including humans suffering from fungal infections. The method comprises systemically or topically administering to a warm blooded animal, including a human, an effective amount of a compound of Formula (I), its N-oxide form, a pharmaceutically acceptable addition salt or possible stereoisomer. Thus, the compounds of formula (I) are provided as medicaments, in particular the use of the compounds of formula (I) in the manufacture of medicaments useful for treating fungal infections.
The invention also provides compositions for treating or preventing fungal infections comprising a compound of formula (I) of a therapeutically effective hem and a pharmaceutically acceptable carrier or diluent.
In view of its useful pharmacological properties, the target compounds of the invention can be formulated in a variety of pharmaceutical forms for administration purposes. In order to prepare a pharmaceutical composition of the present invention, as an active ingredient, a pharmaceutically acceptable carrier which can take various forms depending on the form of the preparation for the purpose of administering a therapeutically effective amount of a specific compound in the form of a base or an addition salt; To a complete mixture of. These pharmaceutical compositions are preferably in unit dosage form suitable for oral administration, rectal administration, topical administration, transdermal administration, nail administration or parenteral injection. For example, when the composition is prepared orally, for example, oral liquid preparations such as suspending agents, syrups, elixirs and solutions, water, glycols, oils, alcohols and the like; Or in the case of powders, pills, capsules and tablets, useful pharmaceutical media such as solid carriers such as starch, sugars, kaolin, lubricants, binders, disintegrating agents and the like can be used. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are explicitly used. As compositions suitable for topical application, mention may be made of all compositions normally used for topical administration, such as creams, gels, dressings, shampoos, tinctures, pastes, ointments, plasters, powders and the like. In compositions suitable for transdermal administration, the carrier optionally comprises a penetration enhancer and / or a suitable wetting agent, optionally in combination with a small amount of suitable additives having certain properties that do not have a very harmful effect on the skin. Such additives may facilitate administration to the skin and / or may be helpful for preparing the desired compositions. Such compositions can be administered in a variety of ways, for example, as transdermal patches, as drops, and as ointments.
The composition through the nail is in the form of a solution, and the carrier optionally contains a penetration enhancer that promotes penetration of the antifungal agent into the nail through the keratinized nail layer of the nail. The solvent medium contains water mixed with an alcohol having 2 to 6 carbon atoms, for example a co-solvent such as ethanol.
For parenteral compositions, the carrier usually contains at least a substantial portion of sterile water. For example, an injection solution may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspending agents may be used in which appropriate liquid carriers, suspending agents and the like may be used. For parenteral compositions, other ingredients may be included that aid in solubility, such as cyclodextrins. Suitable cyclodextrins include those wherein at least one hydroxy group of the anhydroglucose unit of the cyclodextrin is replaced by C _1-6 alkyl (especially methyl, ethyl or isopropyl) (eg randomly methylated β-CD); HydroxyC _1-6 alkyl, in particular hydroxyethyl, hydroxypropyl or hydroxybutyl; CarboxyC _1-6 alkyl, in particular carboxymethyl or carboxyethyl; C _1-6 alkylcarbonyl, in particular α-, β-, γ-cyclodextrin substituted by acetyl or ethers thereof and mixed ethers. Particularly useful as complexes and / or solubilizing agents are β-CD, irregularly methylated β-CD, 2,6-dimethyl-β-CD, 2-hydroxy-β-CD, 2-hydroxyethyl-γ-CD , 2-hydroxypropyl-γ-CD and (2-carboxy-methoxy) propyl-β-CD, and especially 2-hydroxypropyl-β-CD (2-HP-β-CD).
The term mixed ether refers to a cyclodextrin derivative wherein at least two cyclodextrin hydroxy groups are etherified by different groups such as, for example, hydroxy-propyl and hydroxyethyl.
Average molar substitution (M.S.) is used as a measure for the average number of moles of alkoxy units per mole of anhydrous glucose. Average degree of substitution (D.S.) refers to the average number of hydroxyls substituted per anhydrous glucose unit. M.S. And D.S. Values can be determined by various analytical techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS) and infrared spectroscopy (IR). Depending on the technique used, slightly different values can be obtained for a given cyclodextrin derivative. Preferably, as measured by mass spectroscopy, M.S. Range from 0.125 to 10, and D.S. The range is 0.125-3.
Other compositions suitable for oral or rectal administration include particles obtainable by melt extruding a mixture containing a compound of formula (I) and a suitable water soluble polymer, followed by milling the melt extruded mixture. The particles can then be formulated in pharmaceutical dosage forms such as tablets and capsules by conventional techniques.
The particles consist of a solid dispersion comprising a compound of formula (I) and one or more pharmaceutically acceptable water soluble polymers. A preferred technique for preparing a solid dispersion is a melt-extrusion process, which includes the following steps:
a) mixing the compound of formula (I) with a suitable water soluble polymer,
b) optionally blending the obtained mixture with the additives,
c) heating the blend obtained until a homogeneous melt is obtained,
d) forcing the obtained melt through at least one nozzle;
e) cooling the melt until it solidifies.
The solid dispersion product is milled or milled into particles having a particle size of less than 600 μm, preferably less than 400 μm and most preferably less than 125 μm.
The water-soluble polymer in the particles is a polymer having an apparent viscosity of 1 to 100 mPa · s when dissolved in a 2% aqueous solution at 20 ° C. For example, suitable water soluble polymers include alkylcelluloses, hydroxyalkylcelluloses, hydroxyalkyl alkylcelluloses, carboxyalkylcelluloses, alkali metal salts of carboxyalkylcelluloses, carboxyalkylalkylcelluloses, carboxyalkylcellulose esters, starches, pectin, chitin derivatives, Polysaccharides, polyacrylic acid and salts thereof, polymethacrylic acid and salts thereof, methacrylate copolymers, polyvinyl alcohol, polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone and vinyl acetate, polyalkylene oxides And copolymers of ethylene oxide and propylene oxide. Preferred water-soluble polymers are hydroxypropyl methylcelluloses.
In addition, one or more cyclodextrins may be used as the water soluble polymer in preparing the above-mentioned particles as disclosed in WO 97/18839. Such cyclodextrins include pharmaceutically acceptable unsubstituted and substituted cyclodextrins, more particularly α, β or γ cyclodextrins or pharmaceutically acceptable derivatives thereof, known in the art.
Substituted cyclodextrins that can be used include the polyethers described in US Pat. No. 3,459,731. Further substituted cyclodextrins are those in which the hydrogen of one or more cyclodextrin hydroxy groups is C _1-6 alkyl, hydroxyC _1-6 alkyl, carboxy-C _1-6 alkyl or C _1-6 alkyloxycarbonylC _{1- 6} ether substituted by alkyl or a mixed ether thereof. In particular, such substituted dextrins are those in which the hydrogen of one or more cyclodextrin hydroxy groups is C _1-3 alkyl, hydroxyC _2-4 alkyl or carboxyC _1-2 alkyl, or more particularly methyl, ethyl, hydroxyethyl, hydroxy Ether substituted by oxypropyl, hydroxybutyl, carboxy-methyl or carboxyethyl.
Particularly useful are, for example, Drugs of the Future, Vol. 9, No. 8, p. 577-578 by M. Nogradi (1984)]-cyclodextrin ethers such as dimethyl-β-cyclodextrin, and polyethers such as hydroxypropyl β-cyclodextrin and hydroxyethyl β-cyclodextrin. Such alkyl ethers may be methyl ethers having a degree of substitution of about 0.125 to 3, for example 0.3 to 2. Such hydroxypropyl cyclodextrins can be formed, for example, from the reaction of β-cyclodextrin with propylene oxide and can have an MS value of about 0.125 to 10, for example about 0.3 to 3.
A newer form of substituted cyclodextrin is sulfobutylcyclodextrin.
The ratio of active ingredient to cyclodextrin can vary widely. For example, a ratio of 1/100 to 100/1 can be applied. An interesting ratio of active ingredient to cyclodextrin is in the range of about 1/10 to 10/1. A more interesting ratio of active ingredient to cyclodextrin is in the range of about 1/5 to 5/1.
It may also be convenient to formulate the azole antifungal agents of the invention in the form of nanoparticles having surface modifiers adsorbed on the surface in an amount sufficient to maintain an effective average particle size of less than 1000 nm. Useful surface modifiers are believed to include those that physically adhere to the surface of the antifungal agent but do not chemically bind the antifungal agent.
Suitable surface modifiers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products and surfactants. Preferred surface modifiers include nonionic and anionic surfactants.
Another interesting method of formulating the compounds of the present invention includes pharmaceutical compositions in which the antifungal agent of the present invention is introduced into a hydrophilic polymer and the mixture is applied as a coat film on many small beads, which can be conveniently prepared accordingly. And suitable compositions for the preparation of pharmaceutical dosage forms for oral administration can be obtained.
The beads comprise a circular or spherical core, a coating film of hydrophilic polymer and antifungal agent and a seal-coated polymer layer.
Suitable materials for use as cores in the beads vary as long as they are pharmaceutically acceptable and have the appropriate size and firmness. Examples of such materials are polymers, inorganic materials, organic materials, and saccharides and derivatives thereof.
The pharmaceutical compositions mentioned above may also contain other antifungal compounds, such as fungal effective amounts of cell wall active compounds. As used herein, the term "cell wall active compound" means a compound that interferes with fungal cell walls and is a fungal cell wall inhibitor such as nicomycin, such as nicomycin K and others, as described in US-5,006,513. As well as compounds such as, but not limited to, papelacandine, echinocandine, and aculeacin.
It is particularly advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein and in the claims refers to physically discrete units suited as unitary dosages, each unit containing a predetermined amount of active ingredient calculated to produce the desired therapeutic effect with respect to the required pharmaceutical carrier. . Examples of such dosage unit forms include tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoon preparations, large spoon preparations, and the like, and their divisions. There are segregated multiples.
Those skilled in treating warm-blooded animals suffering from fungal diseases can readily determine the daily therapeutically effective amount from the test results exemplified below. In general, a therapeutically effective amount per day is determined to be 0.05-20 mg per kg of body weight.
Experimental part
Hereinafter, "DMF" means N, N-dimethylformamide, "THF" means tetrahydrofuran, and "DIPE" means diisopropyl ether.
A. Preparation of Intermediates
Example A1
a) (±) -2,4-dihydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -2- (1-methyl in THF (500 mL) A mixture of -2-oxopropyl) -3H-1,2,4-triazol-3-one (0.05 mol) and (+)-(R) -α-methylbenzenemethanamine (0.1 mol) was prepared using titanium (IV ) Hydrogenated at 50 ° C. for 48 h using Pd / C 10% (10 g) as catalyst in the presence of n-butoxide (28.4 g) and thiophene solution (10 mL). The catalyst was filtered off. Pd / C 10% (10 g) was added again. Hydrogenation was continued at 50 ° C. for 48 hours. After uptake of H ₂ , the mixture was cooled, then the catalyst was filtered off and the filtrate was evaporated. The residue was stirred in CH ₂ Cl ₂ (500 mL) and H ₂ O (50 mL) was added. The mixture was acidified with concentrated HCl solution, alkalized with concentrated NH ₄ OH solution, and then filtered over dicalite. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was triturated in DIPE, filtered and dried to give 23.5 g (91%) of [(R ^* , R ^* ) (R) + (R ^* , S ^* ) (R)]-2,4-di Hydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -2- [2-[(1-phenylethyl) amino] -1-methylpropyl] -3H- 1,2,4-triazol-3-one (intermediate 1) was obtained.
b) (±) -2,4-dihydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -2- (1-methyl in THF (500 mL) A mixture of 2-oxopropyl) -3H-1,2,4-triazol-3-one (0.05 mol) and (-)-(S) -α-methylbenzenemethanamine (0.1 mol) was prepared using titanium (VI). ) Hydrogenated at 50 ° C. for 48 hours using Pd / C 10% (3 g) as catalyst in the presence of n-butoxide (28.4 g) and thiophene solution (3 mL). The catalyst was filtered off. Pd / C 10% (10 g) and thiophene solution (10 mL) were added again. Hydrogenation was continued at 50 ° C. for 48 hours. After absorption of H ₂ , the catalyst was filtered off and the filtrate was evaporated. The residue was stirred in CH ₂ Cl ₂ , CH ₃ OH and H ₂ O. The mixture was alkalized with NaOH and then filtered over decalite. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was triturated in DIPE, filtered and dried to 19 g (74%) of [(R ^* , R ^* ) (S) + (R ^* , S ^* ) (S)]-2,4-di Hydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -2- [2-[(1-phenylethyl) amino] -1-methylpropyl] -3H- 1,2,4-triazol-3-one (intermediate 2) was obtained.
c) (±) -2,4-dihydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -2- (in CH ₂ Cl ₂ (150 mL) 1-methyl-2-oxopropyl) -3H-1,2,4-triazol-3-one (0.018 mol), (S) -α-methyl-1-naphthalenemethanamine (0.0187 mol) and sodium tris ( A mixture of acetateoto-O) hydroborate (I-) (0.028 mol) was stirred overnight at room temperature. Dilute NH ₄ OH solution was added. The mixture was stirred for 1 hour. The precipitate was filtered off, washed with H ₂ O and CH ₂ Cl ₂ (20 mL) and then dried. The residue was crystallized from CH ₃ CN. The precipitate was filtered off and dried to make 3.3 g (32%) of [R- (R ^* , S ^* ) (S ^* )]-2,4-dihydro-4- [4- [4- (4-hydro Oxyphenyl) -1-piperazinyl] phenyl] -2- [1-methyl-2-[[1- (1-naphthalenyl) ethyl] amino] propyl] -3H-1,2,4-triazole 3-one (intermediate 108) was obtained.
d) mixture of intermediate 5 (0.0049 mol), 3-pyridinecarboxaldehyde (0.0054 mol) and sodium tris (acetateto-O) hydroborate (I-) (0.0049 mol) in CH ₂ Cl ₂ (150 mL) Was stirred at rt over the weekend. Sodium tris (acetateto-O) hydroborate (I-) (0.0022 mol) was added again. The mixture was stirred at rt for ₂ nights, extracted with CH ₂ Cl ₂ and washed with H ₂ O. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by flash column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 97/3). Pure fractions were collected and the solvent evaporated to 0.8 g of [R- (R ^* , S ^* )]-2,4-dihydro-4- [4- [4- (4-hydroxyphenyl) -1-pi Ferrazinyl] phenyl] -2- [1-methyl-2-[(3-pyridinylmethyl) amino] propyl] -3H-1,2,4-triazol-3-one (intermediate 123) was obtained.
e) A mixture of intermediate 5 (0.042 mol) and benzaldehyde (0.042 mol) in tetrahydrofuran (500 ml) using 10% (2 g) of palladium on activated carbon as catalyst in the presence of 4% thiophene solution (1 ml) And hydrogenated at 50 ° C. After absorption of hydrogen (1 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography on silica gel (eluent 1: CH ₂ Cl ₂ / CH ₃ OH 98/2, eluent 2: CH ₂ Cl ₂ / (CH ₃ OH / NH ₃ ) 95/5). It was. The desired fractions were combined and the solvent was evaporated. The residue was triturated in 2-propanol, filtered and dried to 15 g (71%) of [R- (R ^* , S ^* )]-2,4-dihydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -2- [1-methyl-2-[(phenylmethyl) amino] propyl] -3H-1,2,4-triazol-3-one (Intermediate 107) was obtained.
Table 1a below describes the intermediates prepared according to Example A1a.
Table 1a




Example A2
a) A mixture of intermediate 1 (0.0457 moles) in THF (400 mL) was hydrogenated at 50 ° C. using Pd / C 10% (5 g) as catalyst. After uptake of H _2, followed by the addition of H ₂ O and CH ₂ Cl _2, the filtrate was evaporated and the catalyst was filtered. The residue was triturated in CH ₂ Cl ₂ , filtered and dried to 14 g (75%) of (±)-[(R ^* , R ^* ) + (R ^* , S ^* )]-2- (2 -Amino-1-methylpropyl) -2,4-dihydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -3H-1,2,4-tria Zol-3-one (intermediate 3) was obtained.
b) A mixture of intermediate 3 (0.025 mol) and acetic anhydride (0.03 mol) in CH ₂ Cl ₂ (300 mL) was stirred at room temperature. A mixture of NaHCO ₃ (5 g) in H ₂ O (100 mL) was added. The mixture was stirred for 2 hours and CH ₃ OH was added. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by HPLC (eluent: CH ₂ Cl ₂ / CH ₃ OH 97/3 to 90/10) on silica gel. Two pure fractions were combined and their solvents were evaporated.
The first fraction was separated into its enantiomer by column chromatography (eluent: ethanol / 2-propanol 50/50; column: CHIRALPAK AS). Two pure fractions were combined and their solvents were evaporated. The residue was triturated in 2-propanol, filtered and dried to give 0.37 g (3.2%) of [R (R ^* , R ^* )]-N- [2- [4,5-dihydro-4- [ 4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl] acetamide ( Intermediate 4a) and 2.81 g (25%) of [S (R ^* , R ^* )]-N- [2- [4,5-dihydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl] acetamide (intermediate 4b) was obtained.
The second fraction was separated into its enantiomer by column chromatography (eluent: hexane / 2-propanol / CH ₃ OH 30/55/15; column: CHIRALPAK AD). Two pure fractions were combined and their solvents were evaporated. The residue was triturated in 2-propanol, filtered and dried to afford 0.47 g (4%) of [S (R ^* , S ^* )]-N- [2- [4,5-dihydro-4- [ 4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl] acetamide ( Intermediate 4c) and 3.21 g (28%) of [R (R ^* , S ^* )]-N- [2- [4,5-dihydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl] acetamide (intermediate 4; melting point 264.3 ° C.); [α] ^D ₂₀ = + 10.96 ° @ 20.07 mg / 2 mL DMF).
c) A mixture of intermediate 4 (0.0069 mol) in concentrated HCl (50 mL) was stirred for 48 hours and refluxed. The solvent was evaporated and the residue was dissolved in H ₂ O (50 mL). The mixture was alkalized with NH ₄ OH and extracted with CH ₂ Cl ₂ / CH ₃ OH 80/20 (500 mL). The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was triturated in 2-propanol, filtered and dried to give 2.6 g (92%) of [R (R ^* , S ^* )]-2- (2-amino-1-methylpropyl) -2,4 -Dihydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -3H-1,2,4-triazol-3-one (intermediate 5; melting point 237.2 ° C.) ); [α] ^D ₂₀ = + 1.01 ° @ 19.79 mg / 2 ml DMF).
d) A mixture of intermediate 5 (0.0061 mol) and bis (1,1-dimethylethyl) dicarbonate (0.008 mol) in CH ₂ Cl ₂ (500 mL) was stirred for 2 hours and refluxed. Bis (1,1-dimethylethyl) dicarbonate (0.008 mol) was added again. The mixture was stirred for 2 hours and refluxed. The solvent was evaporated and the residue was triturated in DIPE, filtered and dried to give 3.1 g (100%) of 1,1-dimethylethyl [R (R ^* , S ^* )]-[2- [4- [ 4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl] -1 -Methylpropyl] carbamate (intermediate 6; melting point 218.3 ° C.); [α] ^D ₂₀ = + 19.63 ° @ 20.27 mg / 2 ml DMF).
Example A3
a) Intermediate 1 (0.53 mol) was separated on silica gel by HPLC (eluent: CH ₂ Cl ₂ / 2-propanol 99/1 to 97/3). Five fractions were combined and their solvents evaporated.
The first fraction was triturated in DIPE, filtered and dried to 78.5 g (29%) of [R (R ^* , R ^* ) (R ^* )]-2,4-dihydro-4- [4- [4 -(4-hydroxyphenyl) -1-piperazinyl] phenyl] -2- [2-[(1-phenylethyl) amino] -1-methylpropyl] -3H-1,2,4-triazole- 3-one (Intermediate 7; [a] ^D ₂₀ = + 93.07 ° @ 24.98 mg / 5 ml DMF) was obtained.
The second fraction was boiled in CH ₃ CN. The mixture was stirred and then cooled. The precipitate was filtered off and dried to give 97 g (35%) of [S (R ^* , S ^* ) (S ^* )]-2,4-dihydro-4- [4- [4- (4-hydroxy Phenyl) -1-piperazinyl] phenyl] -2- [2-[(1-phenylethyl) amino] -1-methylpropyl] -3H-1,2,4-triazol-3-one (intermediate 7a ) Was obtained.
b) a mixture of intermediate 7 (0.00976 moles) in acetic acid (50 mL) and methanol (200 mL) was Pd as catalyst in the presence of 4% thiophene and (CH ₂ O) _n (2 g) in methanol (1 mL). Hydrogenated at 50 ° C. with / C 10% (2 g). After absorption of H ₂ , the catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in CH ₂ Cl ₂ . The organic solution was washed with NaHCO ₃ solution, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 98/2). Pure fractions were combined and the solvent was evaporated. The residue was triturated in 2-propanol, filtered and dried to give 3.8 g (74%) of [R (R ^* , R ^* ) (R ^* )]-2,4-dihydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -2- [2- [methyl (1-phenylethyl) amino] -1-methylpropyl] -3H-1,2,4- Triazol-3-one (Intermediate 8; [a] ^D ₂₀ = + 17.69 ° @ 24.31 mg / 5 ml DMF) was obtained.
Example A4
a) 2,4-dihydro-4- [4- [4- (4-methoxyphenyl) -1-piperazinyl] phenyl] -3H- in 1-methyl-2-pyrrolidinone (250 mL) A mixture of 1,2,4-triazol-3-one (0.05 mol), ethyl 2-bromobutanoate (0.055 mol) and Na ₂ CO ₃ (0.15 mol) was stirred at 75 ° C. overnight. Ethyl 2-bromobutanoate (0.015 mol) was added again. The mixture was stirred at 75 ° C. for 6 hours and at room temperature for 48 hours, then poured into H ₂ O and stirred for 30 minutes. The precipitate was filtered off and dissolved in CH ₂ Cl ₂ . The solution was filtered. The filtrate is dried, filtered and the solvent is evaporated. The residue was triturated in DIPE and ethyl acetate, filtered and dried to give 10 g (43%) of (±) -ethyl α-ethyl-4,5-dihydro-4- [4- [4- (4 -Methoxyphenyl) -1-piperazinyl] phenyl] -5-oxo-1H-1,2,4-triazole-1-acetate (intermediate 9) was obtained.
b) A mixture of NaHSO ₃ (1 g) in CH ₃ COOH / HBr (250 mL) and 48% HBr (250 mL) was stirred for 15 minutes. Intermediate 9 (0.022 mol) was added. The mixture was stirred for 90 minutes and refluxed. The solvent was evaporated. Toluene was added and the solvent was evaporated. The residue was dissolved in CH ₃ OH. The mixture was stirred on an ice bath. SOCl ₂ (24 g) was added dropwise and the mixture was stirred overnight. The solvent was evaporated and the residue dissolved in CH ₂ Cl ₂ . The organic solution was washed with NaHCO ₃ solution, dried, filtered and the solvent was evaporated. The residue was triturated in DIPE, filtered and dried to 6.6 g of (±) -methyl α-ethyl-4,5-dihydro-4- [4- [4- (4-hydroxyphenyl) -1 -Piperazinyl] phenyl] -5-oxo-1H-1,2,4-triazole-1-acetate (intermediate 10) was obtained.
c) (-)-(2S, cis) -2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) in DMF (100 mL) A mixture of -1,3-dioxolane-4-methanol methanesulfonate (ester) (0.007 mol), intermediate 10 (0.0068 mol) and NaOH (0.008 mol) was stirred overnight at 50 ° C. under N ₂ flow, and then H Pour into ₂ O and stir for 1 h. The precipitate was filtered off and dissolved in CH ₂ Cl ₂ . The organic solution was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH / hexanes / ethyl acetate 48/2/20/30). Pure fractions were combined and the solvent was evaporated. The residue was triturated in ethyl acetate, filtered and dried to 1.4 g (29%) of (2S, cis) -4- [4- [4- [4-[[2- (2,4-difluoro) Lophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl]- α-ethyl-4,5-dihydro-5-oxo-1H-1,2,4-triazole-1-acetate (intermediate 11) was obtained.
d) A mixture of intermediate 11 (0.009 mol) and NaBH ₄ (0.045 mol) in H ₂ O (100 mL) and dioxane (300 mL) was stirred at rt overnight. Saturated NH ₄ Cl solution (100 mL) was added. The mixture was stirred for 3 hours. HCl (10 mL) was added. The mixture was stirred for 48 h, neutralized with Na ₂ CO ₃ solution and extracted with CH ₂ Cl ₂ . The organic layer was separated, washed, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 96/4). Pure fractions were combined and the solvent was evaporated. The residue was triturated in DIPE, filtered and dried to 4.2 g (68%) of (2S, cis) -4- [4- [4- [4-[[2- (2,4-difluoro) Phenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2 , 4-Dihydro-2- [1- (hydroxymethyl) propyl] -3H-1,2,4-triazol-3-one (intermediate 12) was obtained.
e) A mixture of intermediate 12 (0.01 mol) and methanesulfonyl chloride (0.0131 mol) in CH ₂ Cl ₂ (100 mL) was stirred. N, N-bis (1-methylethyl) ethanamine (3 mL) was added and the mixture was stirred overnight and then poured into H ₂ O. The organic layer was separated, washed, dried, filtered and the solvent was evaporated. The residue was dissolved in ethyl acetate. The mixture was filtered through decalite and the filtrate was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 98/2). The pure fractions were combined and the solvent evaporated to give 8.2 g of (2S, cis) -4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1, 2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [1 -[[(Methylsulfonyl) oxy] methyl] propyl] -3H-1,2,4-triazol-3-one (intermediate 13) was obtained.
Example A5
a) (±) -2,4-dihydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -2- (1-methyl in DMF (700 mL) A mixture of -2-oxopropyl) -3H-1,2,4-triazol-3-one (0.120 mol) was cooled on ice. A solution of potassium tri-sec-butylborohydride 1M in THF (300 mL) was added dropwise. The mixture was warmed to room temperature and poured into aqueous NH ₄ Cl solution. The precipitate was filtered off and dried and crystallized from 2-propanol. This fraction was separated by its enantiomer on CHIRALPAK AD (Amyrose 3,5-dimethylphenyl carbamate) purchased from Daicel Chemical Industries, Ltd. in Japan (eluent: 100% ethanol). Two pure fraction groups were combined and their solvents were evaporated. The desired fractions were recrystallized from methanol. The precipitate was filtered off and dried to give 0.9 g of [R- (R ^* , R ^* )]-2,4-dihydro-2- (2-hydroxy-1-methylpropyl) -4-4- [4- [ 4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -3H-1,2,4-triazol-3-one (intermediate 14a; [α] ^D ₂₀ = + 10.35 ° @ 48.81 mg / 5 mL DMF) and 0.8 g of [S- (R ^* , R ^* )]-2,4-dihydro-2- (2-hydroxy-1-methylpropyl) -4-4- [4- [4 -(4-hydroxyphenyl) -1-piperazinyl] phenyl] -3H-1,2,4-triazol-3-one (intermediate 14b) was obtained.
b) reaction under N ₂ flow. (-)-(2S, cis) -2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1 in DMF (150 mL) A mixture of, 3-dioxolane-4-methanol-4-methylbenzenesulfonate (ester) (0.012 mol), intermediate (14a) (0.0109 mol) and NaOH (0.011 mol) was stirred at 70 ° C. overnight. The reaction mixture was cooled down and poured into water. The precipitate was filtered off and dried. This fraction was purified by Silica Motrex Amicon (20-45 μm; eluent: Cl ₃ CCH ₃ / C ₂ H ₅ OH 90/10). Pure fractions were combined and the solvent was evaporated. The residue was triturated in methanol and dried to give 5.3 g of [2S- [2α, 4α (S ^* , S ^* )]]-4- [4- [4- [4-[[2- (2,4- Difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- (2-hydroxy-1-methylpropyl) -3H-1,2,4-triazol-3-one (intermediate 15; [α] ^D ₂₀ = -7.71 ° @ 48.61 mg / 5 ml DMF) was obtained.
c) A mixture of pyridine (200 mL) and intermediate 15 (0.0465 mol) in CH ₂ Cl ₂ (250 mL) was stirred on ice. Methanesulfonyl chloride (0.065 mol) was added. The mixture was allowed to warm to rt and stirred overnight. Methanesulfonyl chloride (0.026 mol) was added again. The mixture was stirred overnight. The solvent was evaporated and the residue dissolved in CH ₂ Cl ₂ . The organic solution was washed, dried, filtered and the solvent was evaporated. The residue was triturated in DIPE, filtered and dried to give 34 g (95.5%) of [2S- [2α, 4α (S ^* , S ^* )]]-4- [4- [4- [4- [ [2- (2,4-Difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl]- 1-piperazinyl] phenyl] -2,4-dihydro-2- [1-methyl-2-[(methylsulfonyl) oxy] propyl) -3H-1,2,4-triazol-3-one (Intermediate 16; Melting Point 172.0 ° C .; [α] ^D ₂₀ = -6.96 ° @ 23.69 mg / 5 ml DMF) were obtained.
Example A6
a) (±) -2,4-dihydro-4- [4- [4- (4-methoxyphenyl) -1-piperazinyl] phenyl] -2- (1-methyl in THF (350 mL) 2-oxopropyl) -3H-1,2,4-triazol-3-one (0.05 mol) and 1- (phenylmethyl) -4-piperidinamine (0.13 mol) were mixed with 4% thiophene. 16 hours at 140 ° C. under pressure of H ₂ (50 atm) and CO ₂ (10 atm) using Pd / C 10% (3 g) as catalyst in the presence of solution (3 mL) and CaH ₂ (0.125 mol) Stirred in the autoclave. The mixture was cooled. The catalyst was filtered off to evaporate the filtrate. The residue was triturated in 2-propanol, filtered and then dried. The residue was boiled in CH ₃ CN (400 mL). The mixture was cooled for 15 minutes. The precipitate was filtered off and dried. The residue was crystallized with CH ₃ CN / dioxane 50/50. The precipitate was filtered off and dried to give 14.8 g (50%) of (±)-(R ^* , S ^* )-2,4-dihydro-4- [4- [4- (4-methoxyphenyl) -1- Piperazinyl] phenyl] -2- [2-[[1- (phenylmethyl) -4-piperazinyl] amino] -1-methylpropyl] -3H-1,2,4-triazol-3-one (Intermediate 17a) was obtained.
The filtrates were combined and evaporated. The residue was triturated in DIPE, filtered and dried. This fraction was purified by HPLC (eluent: CH ₂ Cl ₂ / CH ₃ OH 100/0 to 95/5; column: AMICON 20 μm). The desired fractions were collected and the solvent was evaporated. The residue was boiled in 2-propanol. After cooling, the precipitate was filtered and watered down to 7.2 g (24%) of (±)-(R ^* , R ^* )-2,4-dihydro-4- [4- [4- (4-methoxyphenyl ) -1-piperazinyl] phenyl] -2- [2-[[1- (phenylmethyl) -4-piperazinyl] amino] -1-methylpropyl] -3H-1,2,4-triazole 3-one (intermediate 17) was obtained.
b) A mixture of intermediate 17 (0.0119 mol) and Na ₂ SO ₃ (1 g) in 48% HBr (100 mL) was stirred for 5 hours and refluxed. The solvent was evaporated and the residue neutralized with NaHCO ₃ solution. The mixture was extracted with CH ₂ Cl ₂ / CH ₃ OH. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was triturated in 2-propanol, filtered and dried to give 6.1 g (88%) of (±)-(R ^* , R ^* )-2,4-dihydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -2- [2-[[1- (phenylmethyl) -4-piperazinyl] amino] -1-methylpropyl] -3H-1, 2,4-triazol-3-one (intermediate 18) was obtained.
Example A7
a) reaction under N ₂ atmosphere. 2- (2-bromoethyl) -2,4-dihydro-4- [4- [4- (4-hydroxyphenyl) -1-pi in 1-methyl-2-pyrrolidinone (25 mL) To a mixture of ferrazinyl] phenyl] -3H-1,2,4-triazol-3-one (0.0054 mol) was added Na ₂ CO ₃ (0.01 mol). The mixture was stirred at 60 ° C. A solution of (+)-(R) -α-methylbenzenemethanamine (0.0065 mol) in 1-methyl-2-pyrrolidinone (25 mL) was added dropwise and the resulting reaction mixture was stirred at 60 ° C. overnight. The reaction mixture was cooled, poured into ice water, and the precipitate was filtered off, washed with water and dried. This fraction was recrystallized from 2-propanol, filtered and dried to give 1.98 g (77%) of (R) -2,4-dihydro-4- [4- [4- (4-hydroxyphenyl)- 1-piperazinyl] phenyl] -2- [2-[(1-phenylethyl) amino] ethyl] -3H-1,2,4-triazol-3-one (intermediate 19) was obtained.
b) reaction under N ₂ atmosphere. 2,4-dihydro-4- [4- [4- (4-methoxyphenyl) -1-piperazinyl] phenyl] -3H-1,2,4-triazol-3-one (0.1 in DMF) Mole) was added to 60% NaH (0.12 mole) and stirred at 50 ° C. for 30 min. A solution of 1-chloro-2-propanone (0.1 mol) in DMF was added dropwise and the resulting reaction mixture was stirred at 50 ° C. overnight. The reaction mixture was cooled, poured into ice water, and the formed precipitate was filtered off, washed with water and dried. This fraction was recrystallized from CH ₂ Cl ₂ / CH ₃ OH. After the precipitate was filtered off, the filtrate was evaporated. The residue was crystallized from methanol, filtered and dried. The residue was combined with the crystallized compound, recrystallized from CH ₂ Cl ₂ / CH ₃ OH, filtered and dried to 0.65 g of 2,4-dihydro-4- [4- [4- (4-meth Oxyphenyl) -1-piperazinyl] phenyl] -2- (2-oxopropyl) -3H-1,2,4-triazol-3-one (intermediate 20) was obtained.
Example A8
1,1-dimethylethyl [1-methyl-2- (methylamino) propyl] (phenylmethyl) carbamate (0.005 mol) in dioxane (50 mL) and phenyl prepared according to the method described in EP-A-0,228,125 Cis-4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-diox A mixture of solan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] carbamate (0.005 mol) was stirred overnight and refluxed. The solvent was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH / ethyl acetate / hexane 48/2/30/20). The pure fractions were combined and the solvent evaporated to 2.7 g of 1,1-dimethylethyl (2S, cis) -2-[[[[4- [4-[[2- (2,4-difluorophenyl) -2 -(1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] amino] carbonyl] methyl Amino] -1-methylpropyl] (phenylmethyl) carbamate (intermediate 133) was obtained.
Example A9
Reaction under N ₂ atmosphere. A mixture of intermediate 110 (0.745 moles) in THF (3000 mL) was stirred at 40 ° C. for 1 hour. The mixture was cooled to 30 ° C. 2M LiBH ₄ in THF (0.800 mol) was added dropwise at 30 ° C. After addition of 100 ml, the reaction mixture was slowly warmed to 60 ° C. and the remaining LiBH ₄ was added dropwise. The reaction mixture was then stirred for ± 60 hours and refluxed (65 ° C.). The reaction mixture was cooled down. 2-propanone (500 mL) was added dropwise. Water (800 mL) was added over 1.5 hours. More water (2 L) was added. A solution of NH ₄ Cl (350 g) in water (1.5 L) was added and the mixture was stirred for 2 hours. The layers were separated, the organic layer dried, filtered and the solvent was evaporated. The residue was stirred in DIPE (2 L), filtered and then dried. This fraction was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 95/5). The desired fractions were combined and the solvent evaporated to 120 g (32.6%) of [B (S)]-2,4-dihydro-2- [2-[[1- (hydroxymethyl) -2-methylpropyl] Amino] -1-methylpropyl] -4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -3H-1,2,4-triazol-3-one (intermediate) 104).
Example A10
a) [S- (R ^* , S ^* )]-2,4-dihydro-2- (2-hydroxy-1-methylpropyl) -4- [4- [in CH ₂ Cl ₂ (100 mL) 4- (4-methoxyphenyl) -1-piperazinyl] phenyl] -3H-1,2,4-triazol-3-one (0.012 mol), p-toluenesulfonyl chloride (0.012 mol), tri A mixture of ethylamine (2 g) and dimethylaminopyridine (0.5 g) was stirred at room temperature for 4 days. The mixture was dissolved in CH ₂ Cl ₂ and purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ 100%). Pure fractions were combined and the solvent was evaporated. The residue was triturated in methylisobutyl ketone, filtered and dried to 4.6 g (79%) of [S- (R ^* , S ^* )]-2,4-dihydro-4- [4- [4 -(4-methoxyphenyl) -1-piperazinyl] phenyl] -2- [1-methyl-2-[[(4-methylphenyl) sulfonyl] oxy] propyl] -3H-1,2,4- Triazol-3-one (intermediate 134) was obtained.
b) A mixture of intermediate 134 (0.0071 mol) and sodium azide (0.009 mol) in DMF (50 mL) was stirred at 80 ° C. for 1 hour and 100 ° C. for 4 hours and then cooled. H ₂ O was added and the mixture was left to crystallize. The precipitate was filtered off, washed with H ₂ O and dissolved in CH ₂ Cl ₂ . The organic solution was dried, filtered and the solvent was evaporated to give 2.8 g (88%) of [S- (R ^* , R ^* )]-2- (2-azido-1-methylpropyl) -2,4 -Dihydro-4- [4- [4- (4-methoxyphenyl) -1-piperazinyl] phenyl] -3H-1,2,4-triazol-3-one (intermediate 87) was obtained. .
c) A mixture of intermediate 87 (0.0062 mol) and triphenylphosphine (0.008 mol) in THF (100 mL) was stirred at 50/60 ° C. for 24 h. Water (1 mL) was added. The mixture was stirred at 50/60 ° C. for 8 hours. The solvent was evaporated. The residue was stirred in H ₂ O (100 mL) and concentrated HCl solution (5 mL). The mixture was filtered. The filtrate was washed three times with CH ₂ Cl ₂ , neutralized with NaHCO ₃ solution and extracted with 90/10 CH ₂ Cl ₂ / CH ₃ OH. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was crystallized from ethanol. The precipitate was filtered off and dried to obtain 1.36 g (52%) of [S- (R ^* , R ^* )]-2- (2-amino-1-methylpropyl) -2,4-dihydro-4- [ 4- [4- (4-methoxyphenyl) -1-piperazinyl] phenyl] -3H-1,2,4-triazol-3-one (intermediate 88) was obtained.
d) A mixture of intermediate 105 (0.049 mol) in water (200 mL) and THF (300 mL) was used at room temperature using 10% (4 g) of palladium on activated carbon as catalyst in the presence of 4% thiophene solution (4 mL). Hydrogenated at. After absorption of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was purified via silica gel on a glass filter (eluent 1: CH ₂ Cl ₂ / CH ₃ OH 99/1 and eluent 2: CH ₂ Cl ₂ / (CH ₃ OH / NH ₃ ) 95/5) . Pure fractions were collected and the solvent evaporated to 18.6 g (90%) of [R- (R ^* , S ^* )]-2- (2-amino-1-methylpropyl) -2,4-dihydro-4- [4- [4- (4-methoxyphenyl) -1-piperazinyl] phenyl] -3H-1,2,4-triazol-3-one (intermediate 106) was obtained.
Example A11
a) 2,4-dihydro-4- [4- [4- (4-methoxyphenyl) -1 in methylbenzene (100 mL) and 1,3-dimethyl-2-imidazolidinone (250 mL) A mixture of piperazinyl] phenyl] -3H-1,2,4-triazol-3-one (0.1 mol) and KOH powder (0.1 mol) was stirred at 140 ° C. under a N ₂ flow for 15 minutes, Cool to 80 ° C. 1-[(4-methylphenyl) sulfonyl] -4-piperidinol methanesulfonate (ester) (0.12 mol) was added. The mixture was stirred at 140 ° C. for 24 hours and then cooled. The precipitate was filtered off ( ^* ). The filtrate was poured into ice and extracted three times with toluene. The combined organic layers were washed twice with H ₂ O, dried (MgSO ₄ ), filtered and the solvent was evaporated. ^(*) It was refluxed in a precipitate CH ₂ Cl ₂ (1000 ㎖) and CH ₃ OH (500 ㎖). The precipitate was filtered hot, left to crystallize, filtered and dried in vacuo at 60 ° C. (8.6 g obtained). A portion (1 g) of this fraction was dried at 60 ° C. in vacuo for 28 hours. Yield: 4- [4,5-dihydro-4- [4- [4- (4-methoxyphenyl) -1-piperazinyl] phenyl] -5-oxo-1H-1,2,4- Triazol-1-yl] -1-[(4-methylphenyl) sulfonyl] piperidine (intermediate 135).
b) Intermediate 135 (0.027 mol) was added to a mixture of NaHCH ₃ (2 g) in HBr / CH ₃ OH (150 mL) and 48% HBr (300 mL). The mixture was stirred for 4 hours, refluxed and cooled. The solvent was evaporated. The residue was dissolved in water (300 mL) and aqueous 28% NH ₃ (50 mL) was added. The precipitate was filtered off and dried in vacuo at 75 ° C. (7.5 g (66%) obtained). A portion (1 g) of this fraction was recrystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 2,4-dihydro-4- [4- [4- (4-hydroxyphenyl) -1-piperazinyl] phenyl] -2- (4-piperidinyl) -3H-1,2 , 4-triazol-3-one (intermediate 136).
Example A12
a) Pd / C 10% (3 g) as a catalyst with a mixture of 1,4-dioxaspiro [4.5] decane-8-one (0.115 mol) and hydrazinecarboxaldehyde (0.23 mol) in methanol (300 ml) Hydrogenated at 50 ° C., 100 atm for 16 h. After absorption of hydrogen (1 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in CH ₂ Cl ₂ (750 mL). The organic solution was washed with H ₂ O (100 mL), dried (MgSO ₄ ), and then filtered to evaporate the solvent. Yield: 19.9 g (86%) of 2- (1,4-dioxaspiro [4.5] -decan-8-yl) hydrazinecarboxaldehyde (intermediate 137).
b) Intermediate 137 (0.0995 mol) in methylbenzene (300 mL), phenyl [4- [4- (4-methoxyphenyl) 1-piperazinyl] phenyl] carbamate (0.09 mol) and N, N-dimethyl The mixture of -4-pyridinamine (0.0995 moles) was stirred at 80 ° C. using a Dean Stark apparatus for 16 hours, then stirred and refluxed for 3 hours and cooled. H ₂ O (200 mL) was added and the mixture was extracted with CH ₂ Cl ₂ . The organic layer was separated and washed once with H ₂ O once with NaCl solution, then dried (MgSO ₄ ), filtered and the solvent was evaporated. The residue was crystallized from 2-propanol. The precipitate was filtered off and dried. Yield: 32.3 g (73%). A portion (3 g) of this fraction was recrystallized from 2-propanol. The precipitate was filtered off and dried. This fraction was purified by flash chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 98.5 / 1.5). Pure fractions were combined and the solvent was evaporated. The residue was crystallized from 2-propanol. The precipitate was filtered off and dried. Yield: 2- (1,4-dioxaspiro [4.5] decan-8-yl) -2,4-dihydro-4- [4- [4- (4-methoxyphenyl) -1-pipera Genyl] phenyl] -3H-1,2,4-triazol-3-one (intermediate 138).
c) A mixture of intermediate 138 (0.059 mol) in 10% H ₂ SO ₄ (500 mL) was stirred at 60 ° C. for 3 hours and cooled to room temperature. The precipitate was filtered off and suspended in H ₂ O (300 mL). The mixture was neutralized with saturated K ₂ CO ₃ solution. The precipitate was filtered off, washed twice with H ₂ O and dried. This fraction was triturated in 1: 1 ethanol / CH ₂ Cl ₂ , filtered and dried. This fraction was purified by flash column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 97/3). Pure fractions were combined and the solvent was evaporated. The residue was dried in vacuo. Yield: 2,4-dihydro-4- [4- [4- (4-methoxyphenyl) -1-piperazinyl] phenyl] -2- (4-oxocyclohexyl) -3H-1,2 , 4-triazol-3-one (intermediate 139).
d) A mixture of intermediate 139 (0.031 mol) and benzenemethanamine (0.018 mol) in THF (150 mL) and methanol (150 mL) was Pd / C as catalyst in the presence of 4% thiophene solution (2 mL) in DIPE. Hydrogenated at 50 ° C. using 10% (2 g). After uptake of H ₂ (1 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by flash column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 100/0 to 98/2). Two pure fractions were combined and their solvents were evaporated. The residue was dried at 60 ° C. in vacuo. Yield: (±) -cis-2,4-dihydro-4- [4- [4- (4-methoxyphenyl) -1-piperazinyl] phenyl] -2- [4-[(phenylmethyl ) G] amino] cyclohexyl] -3H-1,2,4-triazol-3-one (intermediate 140) and (±) -trans-2,4-dihydro-4- [4- [4- ( 4-methoxyphenyl) -1-piperazinyl] phenyl] -2- [4-[(phenylmethyl) amino] cyclohexyl] -3H-1,2,4-triazol-3-one (intermediate 144) 1.4 g.
Example A13
A mixture of intermediate 76 (0.0228 mol) in THF (200 mL) was hydrogenated at 125 ° C. for 64 hours using Pt / C 5% (2 g) as catalyst. After uptake of H ₂ (1 equiv), the catalyst was filtered off and the filtrate was evaporated. Yield: (R) -1- [4- [4- (4-methoxyphenyl) -1-piperazinyl] phenyl] -3- [2-[(1-phenylethyl) amino] -1,2 10 g of dimethylethyl] -2-imidazolidinone (intermediate 141).
Table 1b describes intermediates prepared in a similar manner to one of the examples above.
Table 1b



Table 1c


B. Preparation of the Final Product
Example B1
a) (-)-(2S, cis) -2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) in DMF (100 mL) -1,3-dioxolane-4-methanol methanesulfonate (ester) (0.0071 mol), 1,1-dimethylethyl [R (R ^* , S ^* )]-[2- [4- [4- [4 -(4-hydroxyphenyl) -1-piperazinyl] phenyl] -4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl] A mixture of carbamate (0.0059 mol) and NaOH pellets (0.012 mol) was stirred at 70 ° C. under N ₂ flow for 2 hours and then cooled. DIPE (100 mL) and H ₂ O (400 mL) were added. The mixture was stirred and then left to crystallize. The precipitate was filtered off, washed with H ₂ O and DIPE, and purified through silica gel on a glass filter (eluent: CH ₂ Cl ₂ / CH ₃ OH 98/2). Pure fractions were combined and the solvent was evaporated. The residue was triturated in DIPE, filtered and dried to 3.24 g (69%) of 1,1-dimethylethyl [2S- [2α, 4α (S ^* , R ^* )]]-[2- [4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolane -4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl] -1-methyl Propyl] carbamate (compound 28; melting point 158.3 ° C.) was obtained.
b) A mixture of CH ₂ Cl ₂ (50 mL) and Compound 28 (0.0038 mol) in CF ₃ COOH (10 mL) was stirred at rt for 4 h and neutralized with NaHCO ₃ solution. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was triturated in 2-propanol, filtered and dried to give 2.4 g (92%) of [2S- [2α, 4α (S ^* , R ^* )]]-2- (2-amino-1-methyl Propyl) -4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1 , 3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-3H-1,2,4-triazol-3-one (Compound 37; Melting point 168.5 ° C.).
Example B2
Compound 37 (0.0034 mole), N-[(1,1-dimethylethoxy) carbonyl] phenylalanine (0.005 mole) and N '-(ethylcarbonimidolyl) -N, N in CH ₂ Cl ₂ (100 mL) A mixture of dimethyl 1,3-propanediamine (0.005 mol) was stirred for 2 hours at room temperature. The mixture was washed twice with H ₂ O, dried, filtered and the solvent evaporated. The residue was triturated in 2-propanol, filtered and dried to 2.78 g (87%) of 1,1-dimethylethyl [2S- [2α, 4α [(S ^* , R ^* ) (R ^* )]] ]-[2-[[2- [4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazole- 1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -4,5-dihydro-5-oxo-1H-1,2,4 -Triazol-1-yl] -1-methylpropyl] amino] -2-oxo-1- (phenylmethyl) ethyl] carbamate (Compound 124; melting point 181.7 ° C.) was obtained.
Example B3
[2S- [2α, 4α (R ^* , R ^* )]]-2- (2-amino-1-methylpropyl) -4- [4- [4- [4- in CH ₂ Cl ₂ (100 mL) [[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl To a stirred mixture of] -1-piperazinyl] phenyl] -2,4-dihydro-3H-1,2,4-triazol-3-one (0.00436 mol) was added chloro acetylchloride (0.005 mol). . A mixture of NaHCO ₃ (1 g) in water (50 mL) was added. The mixture was stirred at rt for 4 h. The organic layer was separated and dried, filtered and the solvent was evaporated. The residue was crystallized from 2-propanol. The precipitate was filtered off and dried to give 2.8 g (84%) of [2S- [2α, 4α (R ^* , R ^* )]]-2-chloro-N- [2- [4- [4- [4- [ 4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy ] Phenyl] -1-piperazinyl] phenyl] -4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl] acetamide (Compound 33 Melting point 126.8 ° C.).
Example B4
a) A mixture of compound 37 (0.0043 mol) and (S) -phenyl oxirane (0.005 mol) in 2-propanol (50 mL) was stirred overnight and refluxed. (S) -phenyl oxirane (0.005 mol) was added again. The mixture was stirred for 3 hours and refluxed. The solvent was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 99/1). Pure fractions were combined and the solvent was evaporated. The residue was triturated in DIPE, filtered and dried to 1.6 g (47%) of [2S- [2α, 4α [(S ^* , R ^* ) (R ^* )]]]-4- [4- [ 4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl ] Methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(2-hydroxy-2-phenylethyl) amino] -1-methylpropyl] -3H -1,2,4-triazol-3-one (compound 81) was obtained.
b) A mixture of (R) -phenyl oxirane (0.016 mol) in ethanol (50 mL) was stirred. Diethyl amine was bubbled through the mixture for 2 hours. The solvent was evaporated. The residue was dissolved in a mixture of triethylamine (0.08 mol) in diethyl ether (30 mL). The mixture was stirred on ice. Methanesulfonyl chloride (0.015 mol) was added dropwise. The mixture was stirred at rt for 30 min. Compound 37 (0.0027 mol) was dissolved in DMF (20 mL) and HO (4 mL) and then added to the reaction mixture. The mixture was stirred overnight, poured into H ₂ O and extracted with CH ₂ Cl ₂ . The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / (CH ₃ OH / NH ₃ ) 98/2). Pure fractions were combined and the solvent was evaporated. The residue was triturated in DIPE and ethyl acetate, filtered and dried to give 1.1 g (45.8%) of [2S- [2α, 4α [(S ^* , R ^* ) (S ^* )]]]-4- [ 4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolane- 4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -4- [2-[[2- (dimethylamino) -1-phenylethyl] amino] -1-methylpropyl] -2,4 -Dihydro-3H-1,2,4-triazol-3-one (compound 172) was obtained.
Example B5
a) [2S- [2α, 4α (S ^* , S ^* )]]-4- [4- [4- [4-[[2- (2,4-difluorophenyl) in DMF (50 mL) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4 Of dihydro-2- [1-methyl-2-[(methylsulfonyl) oxy] propyl] -3H-1,2,4-triazol-3-one (0.0039 mol) and NaN ₃ (0.005 mol) The mixture was stirred at 85 ° C. for 48 h, poured into H ₂ O and stirred for 30 min. The precipitate was filtered off and dissolved in CH ₂ Cl ₂ . The organic solution was washed, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 98/2). Pure fractions were combined and the solvent was evaporated. The residue was triturated in DIPE and 2-propanol, filtered and dried to give 1.1 g (41%) of [2S- [2α, 4α (R ^* , S ^* )]]-2- (2-azido- 1-methylpropyl) -4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl ) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl-2,4-dihydro-3H-1,2,4-triazol-3-one (compound 19) was obtained.
b) (2S, cis) -4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- in 1-methyl-2-pyrrolidinone (50 mL) (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro -2- [2-[(methylsulfonyl) oxy] ethyl-3H-1,2,4-triazol-3-one (0.0093 mol), (-)-(S) -α-methyl-benzenemethanamine (0.015 mol) and Na ₂ CO ₃ (0.02 mol) were stirred at 100 ° C. for 5 hours and then cooled. Water was added. 2-propanol was added. The mixture was left to crystallize. The precipitate was filtered off, washed with water and dried. The residue was purified via silica gel on a glass filter (eluent: CH ₂ Cl ₂ / CH ₃ OH (1) 99/1, (2) 98/2). Pure fractions were combined and the solvent was evaporated. The residue was crystallized from 2-propanol. The precipitate was filtered off and dried to give 4.6 g (64%) of [2S- [2α, 4α (R ^* )]]-4- [4- [4- [4-[[2- (2,4-di Fluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(1-phenylethyl) amino] ethyl] -3H-1,2,4-triazol-3-one (compound 115; melting point 110.2 ° C.) was obtained. .
c) (2S, cis) -4- [4- [4- [4-[[2- (2,4-difluoro) in (+)-(R) -α-methylbenzenemethanamine (20 mL) Phenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2 , A mixture of 4-dihydro-2- [1-methyl-2-[(methylsulfonyl) oxy] ethyl] -3H-1,2,4-triazol-3-one (0.0016 mol) at 140 ° C., After stirring for 4 hours in the autoclave, it was cooled and purified through silica gel on a glass filter (eluent: CH ₂ Cl ₂ 100%). Pure fractions were combined and the solvent was evaporated. The residue was crystallized from DIPE and 2-propanol. The precipitate was filtered off and dried to give 0.52 g (42%) of [2S- [2α, 4α [R ^* (S ^* )]]] + [2S- [2α, 4α [S ^* (S ^* )]]] -4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3 -Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(1-phenylethyl) amino] 1-methylethyl]- 3H-1,2,4-triazol-3-one (compound 118; melting point 114.9 ° C.) was obtained.
d) (2S, cis) -4- [4- [4- [4-[[2- (2,4-difluorophenyl) in 1,3-dimethyl-2-imidazolidinone (20 mL) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4 -Dihydro-2- [1-methyl-2-[(methylsulfonyl) oxy] ethyl] -3H-1,2,4-triazol-3-one (0.00093 mol) and (-)-(S) A mixture of methylbenzenemethanamine (0.0099 moles) was stirred at 140 ° C. for 6 hours under N ₂ flow, then cooled and poured into ice water. The precipitate was filtered off and then recrystallized from DIPE and 2-propanol. The precipitate was filtered off and dried to obtain 0.31 g (43%) of [2S- [2α, 4α [R ^* (R ^* )]]] + [2S- [2α, 4α [S ^* (R ^* )]]] -4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3 -Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(1-phenylethyl) amino] -1-methylethyl] -3H-1,2,4-triazol-3-one (compound 119) was obtained.
Example B6
a) [2S- [2α, 4α (R ^* , S ^* )]] + [2S- [2α, 4α (S ^* , R ^* )]]-4- [4- [4- in methanol (100 mL) [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] meth Methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[[1- (phenylmethyl) -4-piperidinyl] amino] -1-methylpropyl]- A mixture of 3H-1,2,4-triazol-3-one (0.0046 mol) was hydrogenated for 72 hours at room temperature using 10% (2 g) Pd on activated carbon as catalyst. After absorption of H ₂ , the catalyst was filtered off and the filtrate was evaporated. The residue was purified via silica gel on a glass filter (eluent: CH ₂ Cl ₂ / (CH ₃ OH / NH ₃ ) 95/5 → 90/10). Pure fractions were combined and the solvent was evaporated. The residue was triturated in DIPE, filtered and dried to give 3 g (84%) of [2S- [2α, 4α (R ^* , S ^* )]]-4- [4- [4- [4- [ [2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2- (4-piperazinylamino) -1-methylpropyl] -3 H-1,2,4-triazole-3- On diisopropyl ether (1: 1) (compound 63) was obtained.
b) [2S- [2α, 4α (R ^* , S ^* )]] + [2S- [2α, 4α (S ^* , R ^* )]]-4- [4- [4- in THF (250 mL) [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] meth Methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[[1- (phenylmethyl) -4-piperidinyl] amino] -1-methylpropyl]- A mixture of 3H-1,2,4-triazol-3-one (0.006 mol) was hydrogenated for 3 days using 10% (2 g) Pd on activated carbon as catalyst. Then paraformaldehyde (0.006 mol) and 4% thiophene solution (2 mL) were added. Hydrogenation was continued at 50 ° C. After absorption of H ₂ , the mixture was cooled. The catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / (CH ₃ OH / NH ₃ ) 95/5). Pure fractions were combined and the solvent was evaporated. The residue was crystallized from 2-propanol. The precipitate was filtered off and dried to give 3.2 g (68%) of [2S- [2α, 4α (R ^* , S ^* )]] + [2S- [2α, 4α (S ^* , R ^* )]]-4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolane -4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(1-methyl-4-piperidinyl) amino] -1-methyl Propyl] -3H-1,2,4-triazol-3-one (Compound 64) was obtained.
Example B7
1,1-dimethylethyl [2S- [2α, 4α [(R ^* , R ^* ) (R ^* )]]]-[2- [in methanol (80 mL) and HCl / 2-propanol 6N (20 mL) [2- [4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl)- 1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -4,5-dihydro-5-oxo-1H-1,2,4-triazole-1- A mixture of il] -1-methylpropylamino] -2-oxo-1- (phenylmethyl) ethyl] carbamate (0.0058 mol) was stirred overnight at room temperature. After evaporation, the residue was triturated in CH ₃ CN, filtered and dried. The residue was dissolved in toluene (200 mL). The mixture was stirred for 8 hours using a water separator and refluxed. The precipitate was filtered off, washed with toluene, triturated in mortar and dried. This fraction was dissolved in toluene (200 mL). The mixture was stirred using a water separator and refluxed. H ₂ O (20 mL) was slowly added dropwise. After removal of all H ₂ O, the mixture was cooled and stirred. The precipitate was filtered off and triturated in mortar and dried. This fraction was converted to the free base using NaHCO ₃ solution and CH ₂ Cl ₂ and then purified via silica gel on a glass filter (eluent: CH ₂ Cl ₂ / CH ₃ OH 96/4). Pure fractions were combined and the solvent was evaporated. The residue was dried and dissolved in CH ₂ Cl ₂ and then converted to hydrochloride (1: 1) with HCl / 2-propanol. The solvent was evaporated. The residue was recrystallized from 2-propanol. The precipitate was filtered off and dried. This fraction was dissolved in CH ₂ Cl ₂ and then converted to hydrochloride (1: 1) with HCl / 2-propanol. The solvent was evaporated. The residue was boiled in 2-propanol. The mixture was cooled. The precipitate was filtered and dried to 2.44 g (48%) of [2S- [2α, 4α [(R ^* , R ^* ) (R ^* )]]]-α-amino-N- [2- [4- [ 4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolane- 4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl ] Benzenepropanamine monohydrochloride (Compound 134) was obtained.
Example B8
[2S- [2α, 4α [A (R ^* )]]]-4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2 in THF (100 mL) -(1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-di Stir a mixture of hydro-2- [2-[(2-hydroxy-1-phenylethyl) amino] -1-methylpropyl] -3H-1,2,4-triazol-3-one (0.0052 mol) It was. 60% NaH (0.01 mol) was added. The mixture was stirred for 15 minutes. Iodomethane (0.01 mol) was added. The mixture was stirred for 1 hour. 60% NaH (0.01 mol) was added again. The mixture was stirred at rt overnight, then poured into H ₂ O and extracted with CH ₂ Cl ₂ . The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified via silica gel on a glass filter (eluent: CH ₂ Cl ₂ / CH ₃ OH 98/2). Pure fractions were combined and the solvent was evaporated. The residue was crystallized from 2-propanol. The precipitate was filtered off and dried to 3.4 g (79%) of [2S- [2α, 4α [A (R ^* )]]]-4- [4- [4- [4-[[2- (2,4) -Difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] Phenyl] -2,4-dihydro-2- [2-[(2-methoxy-1-phenylethyl) amino] -1-methylpropyl] -3α-1,2,4-triazol-3-one (Compound 113) was obtained.
Example B9
[2S- [2α, 4α (R ^* , R ^* )]]-2-chloro-N- [2- [4- [4- [4 in DMF (50 mL) and N-ethylethanamine (4 mL) -[4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] Methoxy] phenyl] -1-piperazinyl] phenyl] -4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl] acetamide ( 0.004 mole) of the mixture was stirred at room temperature for 2 hours. H ₂ O and NaHCO ₃ were added. The precipitate was filtered off, washed with H ₂ O and dried. The residue was purified via silica gel on a glass filter (eluent: CH ₂ Cl ₂ / CH ₃ OH 98/2). Pure fractions were combined and the solvent was evaporated. The residue was crystallized from 2-propanol. The precipitate was filtered off and dried to 2.56 g (80%) of [2S- [2α, 4α (R ^* , R ^* )]]-2-diethylamino-N-2- [4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] meth Methoxy] phenyl] -1-piperazinyl] phenyl] -4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl] acetamide (compound 36; melting point 169.6 ° C.) was obtained.
Example B10
A mixture of compound 37 (0.0029 mol) and benzaldehyde (0.0029 mol) in methanol (250 mL) was hydrogenated at 50 ° C. overnight using 10% (2 g) Pd on activated carbon as catalyst in the presence of thiophene solution (2 mL). I was. After absorption of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 98/2). Pure fractions were combined and the solvent was evaporated. The residue was triturated in DIPE and 2-propanol, filtered and dried to give 1.1 g (48%) of [2S- [2α, 4α (S ^* , R ^* )]]-4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] meth Methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(phenylmethyl) amino] -1-methylpropyl] -3H-1,2,4-triazole 3-one (Compound 106; melting point 154.3 ° C.) was obtained.
Example B11
a) A mixture of benzaldehyde (0.0094 mol) and trimethylsilanecarbonitrile (0.01 mol) in CH ₂ Cl ₂ (50 mL) was stirred for 20 minutes. Compound 37 (0.0022 mol) was added. The mixture was stirred overnight. The solvent was evaporated to give 2 g of [2S- [2α, 4α (S ^* , R ^* )]]-α-[[2- [4- [4- [4- [4-[[2- (2,4) -Difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] Phenyl] -4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl] amino] benzeneacetonitrile (Compound 122) was obtained.
b) Methanol (100 mL) was saturated with HCl. Compound 122 (0.0025 mol) was added. The mixture was stirred for 2 hours with bubbling HCl, then poured into Na ₂ CO ₃ solution and extracted with CH ₂ Cl ₂ . The organic layer was separated, washed, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 98/2). Pure fractions were combined and the solvent was evaporated. The residue was triturated in DIPE, filtered and dried to 0.5 g of [2S- [2α, 4α (S ^* , R ^* )]]-α-[[2- [4- [4- [4- [ 4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy ] Phenyl] -1-piperazinyl] phenyl] -4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl] amino] benzeneacetamide (Compound 123) was obtained.
c) A mixture of compound 122 (0.003 mol) in CH ₃ OH / NH ₃ (200 mL) was hydrogenated overnight using Raney nickel (1 g) as catalyst. After absorption of hydrogen (2 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was triturated in DIPE and 2-propanol, filtered and then dried. The residue was purified by HPLC (eluent (0.5% ammonium acetate in 90/10 H ₂ O / CH ₃ CN) / CH ₃ CN 90/10 → 0/100; column HYPERPREP C18 BDS 8 μm). Two pure fractions were combined and their solvents were evaporated. The residue was triturated in DIPE, filtered and dried to 0.45 g of [2S- [2α, 4α [(S ^* , R ^* ) (A)]]]-2- [2-[(2-amino- 1-phenylethyl) amino] -1-methylpropyl] -4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4 -Triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-3H-1,2,4 -Triazol-3-one (18.7%) (Compound 174) and 0.37 g of [2S- [2α, 4α [(S ^* , R ^* ) (B)]]]-2- [2-[(2- Amino-1-phenylethyl) amino] -1-methylpropyl] -4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2 , 4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-3H-1,2 , 4-triazol-3-one (15.4%) (Compound 178) was obtained.
d) Methanol (150 mL) was saturated with HCl on ice. Compound 122 (0.0025 mol) was added. The mixture was stirred and refluxed for 6 hours with bubbling HCl, then cooled and stirred over weekend at room temperature. The solvent was partially evaporated. The concentrate was poured into Na ₂ CO ₃ solution and extracted with CH ₂ Cl ₂ . The organic layer was separated, washed, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 98/2). The pure fractions were combined and the solvent evaporated to 1 g (60%) of methyl [2S- [2α, 4α (S ^* , R ^* )]]-N- [2- [4- [4- [4- [4- [[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl ] -1-piperazinyl] phenyl] -4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl] -2-phenylglycine (compound 170) was obtained.
Example B12
4- (2-Chloroethyl) morpholine hydrochloride (1.9 g) in dimethyl sulfoxide (100 mL), cis-4- [4- [4- [4- [2- (2,4-dichlorophenyl)- 2- (1H-imidazolyl-1-ylmethyl) -1,3-dioxolan-4-ylmethoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-5-methyl- A mixture of 3H-1,2,4-triazol-3-one (5 g) and potassium hydroxide (2 g) was stirred at room temperature for 24 hours. The reaction mixture was poured into water and extracted with dichloromethane. The organic layer was washed with water, dried, filtered and the solvent was evaporated. The residue was purified by chromatography on silica gel (eluent: CHCl ₃ / methanol 99/1). Pure fractions were combined to evaporate the eluent. The residue was crystallized from 4-methyl-2-pentanone to give 1.4 g (24%) of cis-4- [4- [4- [4-[[2- (2,4-dichlorophenyl) -2- ( 1H-imidazolyl-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-5-methyl- [ 2- (4-morpholinyl) ethyl] -3H-1,2,4-triazol-3-one (Compound 1; melting point 157.6 ° C.) was obtained.
Example B13
Intermediate 110 (0.0037 mol) was stirred in DMF (50 mL) under N ₂ flow. 60% NaH (0.004 mol) was added. The mixture was stirred at 50 ° C. for 1 hour. (-)-(2S-cis) -2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolane- 4-Methanol Methanesulfonate (ester) (0.0045 mol) was added. The mixture was stirred at 80 ° C. for 5 hours and then cooled. H ₂ O was added. The mixture was left to crystallize. The precipitate was filtered off and dried. The residue was purified via silica gel on a glass filter (eluent 1: CH ₂ Cl ₂ / CH ₃ OH / ethyl acetate / n-hexane 49/1/30/20 and eluent 2: CH ₂ Cl ₂ / CH ₃ OH 97/3). Pure fractions were combined and the solvent was evaporated. The residue was crystallized from methanol. The precipitate was filtered off and dried to give 1.73 g (57%) of ethyl [2S- [2α, 4α [A (R ^* )]]]-N-2- [4- [4- [4- [4-[[ 2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl]- 1-piperazinyl] phenyl] -4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl] valine (compound 154) was obtained.
Example B14
A mixture of compound 37 (0.0044 moles) and [(1S) -1-formyl-2-phenylethyl] carbamic acid 1,1-dimethylethyl ester (0.0044 moles) in CH ₂ Cl ₂ (50 mL) was stirred at room temperature It was. Sodium tris (acetateto-O) -hydro-borate (I-) (0.007 mol) was added. The mixture was stirred for 2 hours. The residue was purified by chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 99/1 and 98/2). Pure fractions were combined and the solvent was evaporated. The residue was triturated in DIPE, filtered and dried to give 3.2 g (79%) of 1,1-dimethylethyl [2S- [2α, 4α [(S ^* , R ^* )]]]-[[2 -[4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1, 3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl] -1-methylpropyl] amino] methyl] (phenylmethyl) carbamate (compound 141) was obtained.
Example B15
a) Phenyl cis- [4- [4- [4-[[2- (2,4-difluorophenyl) -2 prepared according to the method described in EP-A-0,228,125 in dioxane (50 mL) -(1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] carbamate (0.005 mol) And a mixture of (S) -1,2-dimethyl-N- (1-phenylethyl) ethanediamine (0.005 mol) for 3 hours. The solvent was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 96/4). Pure fractions were combined and the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried to give 1.8 g (41%) of [2S- [2α, 4α [2 (1R ^* )]]]-N- [4- [4- [4-[[2- (2, 4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl ] Phenyl] -N '-[1-methyl-2-[(1-phenylethyl) amino] propyl] urea trihydrochloride monohydrate (Compound 197) was obtained.
b) Trifluoroacetic acid (15 mL) was added dropwise to a stirred mixture of intermediate 133 (0.0025 mol) in CH ₂ Cl ₂ (150 mL). The mixture was stirred for 4 hours, then poured into H ₂ O and neutralized with Na ₂ CO ₃ . The organic layer was separated, washed, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 96/4). Pure fractions were combined and the solvent was evaporated. The residue was triturated in DIPE and 2-propanol, filtered and dried to 1.42 g (74.7%) of (2S-cis) -N- [4- [4- [4-[[2- (2,4) -Difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] Phenyl] -N'-methyl-N '-[1-methyl-2-[(1-phenylmethyl) amino] propyl] urea (Compound 198) was obtained.
Example B16
A mixture of compound 204 (0.0014 mol) and acetophenone (0.042 mol) in toluene (100 mL) was reacted with Pd / C 10% (1 g) as catalyst in the presence of 1-butanethiol (1 mL; 4% solution in DIPE). Hydrogenated at 150 ° C. for 16 h. After uptake of H ₂ (1 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was triturated in DIPE, filtered and then recrystallized from 2-propanol. The precipitate was filtered off and dried to give 0.51 g (46%) of (2S-cis) -4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H) -1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2 -[1- (1-phenylethyl) -4-piperidinyl] -3H-1,2,4-triazol-3-one (compound 199) was obtained.
Example B17
A mixture of compound 195 (0.0013 mol) in THF (100 mL) was hydrogenated at 125 ° C. (100 atm) for 16 h using Pt / C 5% (0.5 g) as catalyst. After uptake of H ₂ (1 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography on silica gel (eluent: CH ₂ Cl ₂ / CH ₃ OH 98/2). Pure fractions were combined and the solvent was evaporated. The residue was triturated in DIPE, filtered and dried to 0.28 g (28%) of (2S-cis) -1- [4- [4- [4-[[2- (2,4-difluoro) Phenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -4 -[2-[(phenylmethyl) amino] -1-methylethyl] -2-imidazolidinone (compound 196) was obtained.
Tables 2 to 8 below illustrate the compounds of formula (I), which illustrate the invention and are prepared according to one of the examples above.
TABLE 2

TABLE 3

Table 4

Table 5




Table 6

TABLE 7



Table 8

Table 9

Table 10

Table 11

C. Pharmacological Examples
Example C1
The eight isolate panels of Candida species (panel 1) were tested. This panel includes azole-resistant Candida albicans strains. Six different fungi (Panel 2) consisted of three dermatophyte isolates and a single isolate of Aspergillus humigatus, Cryptococcus neoformans and Sporotrix check.
To screen these two panels, a series of test compound solutions were prepared in dimethyl sulfoxide (DMSO). The DMSO solution was then diluted 100-fold and introduced into the CYG broth (see Odds, FC, Antimicrobial Agents and Chemotherapy, 1992, 36, 1727-1737) and yeast cells were washed by turbidity at an initial concentration of 10 ⁴ / ml. Different fungi were inoculated at the determined equivalent concentrations. Cultures were seeded in microdilution plate wells for 48 hours at 37 ° C. for yeast and at different times and temperatures for other fungi. Turbidity was measured to assess proliferation in wells containing test compounds as a percentage of proliferation in controls not containing test compounds, and to determine the lowest concentration of test compound that inhibits proliferation of isolates to 35% or less of control proliferation. Recorded as lowest active dose (LAD).
Compounds 1-4, 6-19, 21-29, 31, 34, 35, 40, 41, 43-47, 49, 50, 52-62, 64, 66, 68, 71-79, 81-86, 93 To 98, 100 to 109, 114 to 121, 130 to 132, 134 to 153, 155 to 190, 197 and 198 for this Candida species, the geometric mean minimum inhibitory concentration (MIC) in the range of 0.01 to 1.0 μM Indicated. Other compounds were not tested or the MIC exceeded 1 μM.
Compounds 1-4, 6-31, 34, 35, 40, 41, 43-50, 52-62, 64-69, 71-86, 91-98, 100-123, 130, 132, 134-139, 142 To 156, 158, 160 to 178, 180 to 182, 184 to 190 and 198 showed MICs in the range of 0.01 to 1.0 μM for other fungi. Other compounds were not tested or the MIC exceeded 1 μM.
Example C2
24 Candida isolates, 8 Aspergillus species isolates, 8 dermatophytes, 10 Zaigomycetes, 10 Fusarium species, 2 Cryptococcus neoformans, and 8 Dematiaseus Hippomycetes panels were used.
Inoculum was prepared as in Example C1 using 2% glucose and except the culture medium was RPMI 1640 buffered with MOPS (see Odds, FC, Antimicrobial Agents and Chemotherapy, 1995, 39, 2051-2060). It was. Test compounds were added to the medium to a final concentration of 10, 3.2, 1.0, 0.32, 0.10, 0.032, 0.010, 0.0032 and 0.0010 μM from DMSO solution. Incubation time and temperature are the same as in Example C1. Once the proliferation turbidity was read by spectrophotometer in the microdilution plate, material samples were removed from the test culture and inoculated in a 10 μl volume on Sabouraud glucose agar plates. Plates were incubated for 48 hours at 37 ° C. for yeast, or at other times and temperatures for other species. The geometric mean minimum fungicide concentration (μM), determined as the lowest concentration of test compound that completely or substantially eliminates the reproduction of fungal proliferation on Sabouraud plates, is determined by compounds 5, 8-10, 14-18, 20-22, 38 to 52, 54, 55, 59 to 63, 65, 66, 68, 71 to 86, 91 to 120, 123, 138 to 143, 145 to 148, 150 to 154, 163 to 165, 167 to 178, 185 to 189, 191, 193, 194, 197, 199 and 203 represent 1-10 μM;
For Aspergillus species 5, 8-10, 14-18, 20-22, 38-52, 54-56, 59-86, 91-120, 123, 138-143, 145-148, 150-153 163 to 165, 167 to 178, 185 to 189, 191, 193, 194, 199 and 203 represent 0.1 to 10 μΜ;
For dermatophytes, compounds 5, 8-10, 14-18, 20-22, 41, 43-47, 49, 50, 52, 54-56, 59-62, 66, 68, 71-83, 85, 86 , 92 to 120, 123, 138 to 143, 145, 163 to 165, 167 to 174, 185 to 188, 193 and 199 represent 0.1 to 10 μM;
For Zaigomycetes compounds 43, 51, 74, 77, 79, 83, 86, 93, 95, 96, 98, 100-102, 107, 108, 120, 138, 143, 146, 163-165, 170, 171, 175, 176, 185-187, 193, 194, and 203 represent 1-10 μM;
For fuslium species compounds 43-46, 54, 60, 61, 73, 74, 77, 83, 86, 100-107, 109, 116, 117, 120, 138, 143, 145, 146, 148, 151, 163, 165, 168, 175 to 177, 186 to 188, 193, 194, 199 and 203 represent 1 to 10 μM;
For other fungi, compounds 5, 8-10, 14-18, 20-22, 38-52, 54-56, 59-86, 91-93, 95-120, 123, 138-143, 145-148 , 150 to 153, 163 to 165, 167 to 178, 185 to 189, 191, 193, 194, 197, 199 and 203 showed 0.1 to 10 μΜ.
Compounds not mentioned above were not tested or the MIC exceeded 10 μΜ.
D. Physical and Chemical Examples
Example D1: Water solubility
Excess compound was added to water buffered with 0.1 M citric acid and 0.2 M Na ₂ HPO ₄ at a ratio of 61.5 / 38.5 (pH = 4). The mixture was shaken for 1 day at room temperature. The precipitate was filtered off. The concentration of the compound was measured by UV spectroscopy. Compound 9, 10, 15-18, 21, 38, 39, 42, 49, 51, 52, 55, 61, 63, 65, 66, 68, 70, 71, 73, 74, 81-86, 93, 100 To 102, 106, 107, 109, 114, 115, 139, 140, 142, 143, 147, 149 to 152, 155 to 159, 172, 174 to 179, 181 to 184, 187, 189 to 191, 193, 194 , 197, 198, 200, 201 and 203 exhibited solubility in excess of 0.1 mg / ml. Other compounds were not tested or exhibited solubility of less than 0.01 mg / ml.
E. Composition Examples
Example E.1: Injection Solutions
1.8 g of methyl 4-hydroxybenzoate and 0.2 g of sodium hydroxide were dissolved in about 0.5 L of injectable boiling water. After cooling to about 50 ° C., 0.05 g of propylene glycol and 4 g of active ingredient were added with stirring. The solution was cooled to room temperature and the water for injection was supplemented with an amount sufficient to make 1 L to obtain a solution containing 4 mg / ml of the active ingredient. The solution was filtered and sterilized and filled into a sterile container.
Example E.2 Composition for Nail Treatment
0.144 g KH ₂ PO ₄ , 9 g NaCl and 0.528 g Na ₂ HPO ₄ 2H ₂ O were added to 800 mL of H ₂ O and the mixture was stirred. After adjusting the pH to 7.4 with NaOH, 500 mg of NaN ₃ was added. Ethanol (42 v / v%) was added and the pH was adjusted to 2,3 with HCl. 15 mg of active ingredient was added to 2.25 mL PBS / ethanol (42%; pH 2.3) and the mixture was stirred and then sonicated. 0.25 mL PBS / ethanol (42%; pH 2.3) was added and the mixture was further stirred and sonicated until all active ingredients dissolved to obtain the desired nail treatment composition.

权利要求:
Claims (13)
[1" claim-type="Currently amended] Compounds of formula (I), their N-oxide forms, pharmaceutically acceptable addition salts and stereochemical isomers:

Where
L is the following general formula

Represents the radical,
From here,
Each Alk independently represents C _1-6 alkanediyl optionally substituted by hydroxy or C _1-4 alkyloxy;
Each n is independently 1, 2 or 3;
Y represents O, S or NR ² ;
Each R ¹ is independently hydrogen, aryl, Het ¹ , or halo, hydroxy, mercapto, C _1-4 alkyloxy, C _1-4 alkylthio, aryloxy, arylthio, arylC _1-4 alkyloxy, ArylC _1-4 alkylthio, cyano, amino, mono- or di (C _1-4 alkyl) amino, mono- or di (aryl) amino, mono- or di (arylC _1-4 alkyl) amino, C _1-4 alkyloxycarbonyl, amino, benzyloxycarbonyl, amino, aminocarbonyl, carboxyl, C _1-4 alkyloxycarbonyl, guanidyl pyridinyl, aryl, and each of the one selected independently from the group consisting of Het ^2, two or C _1-6 alkyl optionally substituted by three substituents;
Each R ² independently represents hydrogen or C _1-6 alkyl;
When R ¹ and R ² are bonded to the same nitrogen atom, they can together form a heterocyclic radical selected from the group consisting of morpholinyl, pyrrolidinyl, piperidinyl, homopiperidinyl and piperazinyl There is; These heterocyclic radicals are optionally C _1-4 alkyl, aryl, Het ² , arylC _1-4 alkyl, Het ² C _1-4 alkyl, hydroxyC _1-4 alkyl, amino, mono- or di (C _{1 -4} alkyl) amino, aminoC _1-4 alkyl, mono- or di (C _1-4 alkyl) aminoC _1-4 alkyl, carboxyl, aminocarbonyl, C _1-4 alkyloxycarbonyl, C _1-4 Or may be substituted by alkyloxycarbonylamino or mono- or di (C _1-4 alkyl) aminocarbonyl; Together they can form azido radicals;
Each R ³ independently represents hydrogen, hydroxy or C _1-4 alkyloxy;
Aryl represents phenyl, naphthalenyl, 1,2,3,4-tetrahydro-naphthalenyl, indenyl or indanyl; Each of these aryl groups is halo, C _1-4 alkyl, hydroxy, C _1-4 alkyloxy, nitro, amino, trifluoromethyl, hydroxyC _1-4 alkyl, C _1-4 alkyloxyC _1-4 Optionally substituted by one or more substituents selected from the group consisting of alkyl, aminoC _1-4 alkyl and mono- or di (C _1-4 alkyl) aminoC _1-4 alkyl;
Het ¹ represents monocyclic or bicyclic heterocyclic radicals wherein the monocyclic heterocyclic radicals are pyridinyl, piperidinyl, homopiperidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, Triazinyl, triazolyl, pyranyl, tetrahydropyranyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, thiazolyl, thiazolidinyl, isothiazolyl, Oxazolyl, oxazolidinyl, isoxazolyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, furanyl, tetrahydrofuranyl, thienyl, thiolyl and dioxolanyl; Bicyclic heterocyclic radicals include quinolinyl, 1,2,3,4-tetrahydro-quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, cinnaolinyl, chromanyl , Thiochromenyl, 2H-chromenyl, 1,4-benzodioxanyl, indolyl, isoindolyl, indolinyl, indazolyl, furinyl, pyrrolopyridinyl, furanopyridinyl, thienopyridinyl, Benzothiazolyl, benzoxazolyl, benzoisothiazolyl, benzisoxazolyl, benzimidazolyl, benzofuranyl and benzothienyl; The mono- or bicyclic heterocycle may each optionally be halo, C _1-4 alkyl, hydroxy, C _1-4 alkyloxy, nitro, amino, trifluoromethyl, hydroxyC _1-4 alkyl, C _{1- 4} alkyloxy-C _1-4 alkyl, aminoC _1-4 alkyl, mono- or di (C _1-4 alkyl) aminoC _1-4 alkyl, one selected from the group consisting of aryl and arylC _1-4 alkyl, Or if possible, substituted by more substituents;
Het ² is the same as Het ¹ and may also be a monocyclic heterocycle selected from the group consisting of piperazinyl, homopiperazinyl, 1,4-dioxanyl, morpholinyl and thiomorpholinyl; Wherein the monocyclic heterocycles are each optionally optionally halo, C _1-4 alkyl, hydroxy, C _1-4 alkyloxy, nitro, amino, trifluoromethyl, hydroxyC _1-4 alkyl, C _1-4 alkyl oxy-C _1-4 alkyl, amino C _1-4 alkyl, mono- or di-one selected from (C _1-4 alkyl) amino C _1-4 alkyl, aryl and aryl C _1-4 group consisting of alkyl, or where possible May be substituted by more substituents;
R ⁶ represents hydrogen or C _1-4 alkyl;
R ⁷ represents hydrogen or C _1-4 alkyl;
R ⁶ and R ⁷ together form a divalent radical of the formula -R ⁶ -R ^7- ,
Where -R ⁶ -R ⁷ -is
-N = CH- (i),
-CH = N- (ii),
-CH = CH- (iii),
-CH ₂ -CH ₂ (iv),
Wherein one hydrogen atom in radicals (i) and (ii) may be substituted by C _1-4 alkyl radicals, and one or more hydrogen atoms in radicals (iii) and (iv) are C _1-4 alkyl radicals May be substituted by;
D is the following general formula

Represents the radical,
From here,
X is N or CH,
R ⁴ is hydrogen or halo;
R ⁵ is halo.
[2" claim-type="Currently amended] A compound according to claim 1, wherein D is a radical of general formula D ₁ .
[3" claim-type="Currently amended] The compound according to claim 1 or 2, wherein L is a radical of formula (a), (b) or (c).
[4" claim-type="Currently amended] 4. The compound of claim 1, wherein Alk is 1,2-ethanediyl, 1,2-propanediyl, 2,3-propanediyl, 1,2-butanediyl, 3,4-butanediyl, 2. , 3-butanediyl, 2,3-pentanediyl or 3,4-pentanediyl
[5" claim-type="Currently amended] 5. The compound of claim ¹ , wherein R ¹ is hydrogen, aryl, Het ¹ , or halo, hydroxy, C _1-4 alkyloxy, aryloxy, arylC _1-4 alkyloxy, cyano, amino , Mono- or di (C _1-4 alkyl) amino, mono- or di (arylC _1-4 alkyl) amino, C _1-4 alkyloxycarbonylamino, aminocarbonyl, aryl and Het ² Each independently represents C _1-6 alkyl optionally substituted by one, two or three substituents selected; R ² represents hydrogen or C _1-6 alkyl; When R ¹ and R ² are bonded to the same nitrogen atom, they together form a heterocyclic radical selected from the group consisting of morpholinyl, pyrrolidinyl, piperidinyl and pyrerazinyl, and these heterocyclic radicals Is C _1-4 alkyl, aryl, arylC _1-4 alkyl, hydroxyC _1-4 alkyl, amino, mono- or di (C _1-4 alkyl) amino, mono- or di (C _1-4 alkyl) Optionally substituted with _{aminoC 1-4} alkyl or C _1-4 alkyloxycarbonylamino; R ¹ and R ² together may also form azido radicals.
[6" claim-type="Currently amended] The compound according to any one of claims 1 to 5, wherein L is a radical of general formula (a-1) or (a-2):

Where
Alk is as defined in claim 1;
Z ¹ is aryl, arylmethyl, arylethyl, Het ¹ or C _1-4 alkyl;
Z ² is hydrogen, carboxyl, C _1-4 alkyloxycarbonyl, aminocarbonyl, or methyl optionally substituted by hydroxy, methoxy, amino, or mono- or di (methyl) amino;
Z ¹ and Z ² together with the carbon atom to which they are attached form a piperidinyl ring substituted by arylmethyl, arylethyl or C _1-4 alkyl;
Z ³ is O, NC _1-4 alkyl or N-aryl.
[7" claim-type="Currently amended] The method of claim 1,
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(1-phenylethyl) amino] -1-methylpropyl]- 3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(2-phenylethyl) amino] -1-methylpropyl]- 3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2- (4-phenyl-1-piperazinyl) -1-methylpropyl ] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(3-phenylpropyl) amino] -1-methylpropyl]- 3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2- [2-[[(2-fluorophenyl) methyl] amino] -1-methylpropyl] -2,4 -Dihydro-3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(phenylmethyl) amino] -1-methylpropyl] -3H- 1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[[(2-methoxyphenyl) methyl] amino] -1- Methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(2-phenoxyethyl) amino] -1-methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(2,3-dihydro-1H-inden-2-yl ) Amino] -1-methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2- [2-[[1- (4-fluorophenyl) ethyl] amino] -1-methylpropyl] -2 , 4-dihydro-3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[[1- (phenylmethyl) -4-piperidinyl] amino ] -1-methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2- (4-morpholinyl) -1-methylpropyl] -3H- 1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[[1- (hydroxymethyl) -2-phenylethyl] amino ] -1-methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(2-hydroxy-1-phenylethyl) amino] -1 -Methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(2-hydroxy-2-phenylethyl) amino] -1 -Methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[[1- (hydroxymethyl) -2-methylpropyl] amino ] -1-methylpropyl] -3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[(1-phenylethyl) amino] -1-methylpropyl]- 3H-1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [1- (1-phenylethyl) -4-piperidinyl] -3H- 1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-dichlorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3-dioxolane -4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [2-[[1- (hydroxymethyl) -2-methylpropyl] amino]- 1-methylpropyl] -3H-1,2,4-triazol-3-one;
2- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-4- [2-[(phenylmethyl) amino] -1-methylpropyl] -3H- 1,2,4-triazol-3-one;
4- [4- [4- [4-[[2- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-ylmethyl) -1,3- Dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro-2- [4-[(phenylmethyl) amino] cyclohexyl] -3H-1,2 , 4-triazol-3-one;
Phosphorus compounds which are N-oxides, pharmaceutically acceptable addition salts and stereochemical isomers thereof.
[8" claim-type="Currently amended] 8. A compound according to any one of claims 1 to 7, wherein the stereoisomerically pure compound.
[9" claim-type="Currently amended] 9. A compound according to any one of claims 1 to 8 for use as a medicament.
[10" claim-type="Currently amended] Use of a compound according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment of fungal infections.
[11" claim-type="Currently amended] A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 as an active ingredient in a pharmaceutically acceptable carrier.
[12" claim-type="Currently amended] Intermediates of Formula (III):

Where
L is as defined in claim 1,
R ^{6 '} and R ^7' are the same as R ⁶ and R ⁷ as defined in claim 1, but are not hydrogen.
[13" claim-type="Currently amended] a) reacting the intermediate of formula (II), wherein W ¹ is a suitable leaving group, with the intermediate of formula (III) in a reaction-inert solvent in the presence of a suitable base;
b) the intermediate of formula (IV) in the reaction-inert solvent in the presence of a base, wherein the intermediate of formula (V), wherein W ² is a suitable leaving group and the primary and secondary amines in L are present N-alkylated with a protecting group P which is a C _1-4 alkyloxycarbonyl group; If L is protected, continue to deprotect L using deprotection techniques known in the art;
c) An intermediate of formula (VI), wherein W ³ is a suitable leaving group, is reacted with an intermediate of formula (VII) or NaN ₃ , optionally in the presence of a suitable base, in a reaction-inert solvent To obtain a compound of formula (I ′), wherein L is a radical of formula (a);
If necessary, the compound of formula (I ') is converted to another compound of formula (I') according to transformations known in the art; Further, if necessary, compounds of general formula (I ′) are treated with acid to convert to therapeutically active nontoxic acid addition salts, or conversely, acid addition salt forms with alkali to convert to free base; If necessary, it is characterized by the preparation of its stereochemically isomeric or N-oxide form, wherein D and L are as defined in claim 1 and R ⁶ and R ⁷ are as defined in claim 1, A process for preparing the compound of general formula (I), which is not hydrogen (wherein R ⁶ and R ⁷ are represented by R ^{6 ′} and R ⁷ ′), is represented by general formula (I ′):

类似技术:

---

公开号 | 公开日 | 专利标题

---

US5466820A|1995-11-14|Production of Di or tri-azolyl substituted 5-keto azole compounds

---

DK166673B1|1993-06-28|4- | phenoles and procedures for preparing thereof

---

KR100386491B1|2003-08-21|Antifungal agents, compounds and methods for their preparation

---

KR100365312B1|2003-03-06|N- [4- | phenyl] heteroarylamine

---

AU665988B2|1996-01-25|Itraconazole and saperconazole stereoisomers

---

FI78692B|1989-05-31|Foerfarande foer framstaellning av farmaceutiskt anvaendbara triazolfoereningar.

---

US5620994A|1997-04-15|Azolylamine derivative

---

CA2179396C|2001-04-17|Tetrahydrofuran antifungals

---

CA1149386A|1983-07-05|Heterocyclic derivatives of |methyl-1h-imidazoles and1h-1,2,4-triazoles

---

ES2224462T3|2005-03-01|Mimetic anilides of retinoic acid.

---

KR101404862B1|2014-06-09|Novel antifungal triazole derivatives

---

EA010132B1|2008-06-30|Triazole derivatives as vasopressin antagonists

---

CS203098B2|1981-02-27|Fungicide and agent for growth plants regulator and process for preparing efective compound

---

KR970000952B1|1997-01-21|Benzotriazole derivatives substituted 1h-azole-1-ylmethyl

---

US5661151A|1997-08-26|Tetrahydrofuran antifungals

---

FI88505C|1993-05-25|For the preparation of therapeutically active compounds // 4- [4- | phenoxymethyl] -1,3-dioxolan-2-yl] methyl-1H-imidazole and -1H-1,2 4-triazolderivat

---

US4791111A|1988-12-13|[[4-[4-|phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties

---

SK278215B6|1996-04-03|Triazole derivatives, method of preparation thereof, intermediate products of these methods, pharmaceutical and antifungal agent and application of these compounds

---

AU665218B2|1995-12-21|Trisubstituted tetrahydrofuran antifungals

---

CZ20013854A3|2002-04-17|Renin inhibitors

---

KR100227231B1|1999-11-01|Apolipoprotein-b synthesis inhibitors

---

CA2197672C|2011-05-17|Tetrahydrofuran antifungals

---

EP0741737B1|1999-11-10|Watersoluble azole antifungals

---

EP2194046B1|2012-05-09|Triazolone derivative

---

SK4397A3|1997-11-05|Acyl azolones, manufacturing process thereof, pharmauceutical compositions on their base and process for producing them

同族专利:

---

公开号 | 公开日

---

ZA200007459B|2002-09-13|

---

HU0103536A3|2002-08-28|

---

AU4361599A|1999-11-29|

---

CA2331187A1|1999-11-18|

---

JP2002514645A|2002-05-21|

---

BR9910448A|2001-01-02|

---

WO1999058530A1|1999-11-18|

---

EP0957101A1|1999-11-17|

---

TR200003323T2|2001-02-21|

---

CZ20004108A3|2001-05-16|

---

NZ507965A|2002-05-31|

---

DK1077976T3|2002-12-02|

---

PL344037A1|2001-09-24|

---

HK1033312A1|2003-02-21|

---

PL194086B1|2007-04-30|

---

CZ298702B6|2007-12-27|

---

IL139647D0|2002-02-10|

---

PL344047A1|2001-09-24|

---

AT238296T|2003-05-15|

---

EP1077975A1|2001-02-28|

---

DE69907171T2|2004-02-05|

---

BG64954B1|2006-10-31|

---

HRP20000741A2|2001-06-30|

---

SK285763B6|2007-07-06|

---

NZ507966A|2002-10-25|

---

NO20005712L|2000-12-07|

---

CA2331141C|2008-10-28|

---

HU0102031A3|2002-10-28|

---

TR200003322T2|2001-02-21|

---

EE04311B1|2004-06-15|

---

TW572899B|2004-01-21|

---

SI1077976T1|2003-02-28|

---

DE69902461T2|2003-04-10|

---

HRP20000740A2|2001-10-31|

---

NO319760B1|2005-09-12|

---

EP1077976B1|2002-08-07|

---

KR20010041480A|2001-05-25|

---

EP1077976A1|2001-02-28|

---

AR016480A1|2001-07-04|

---

AU751135B2|2002-08-08|

---

NO319851B1|2005-09-19|

---

JP2002514646A|2002-05-21|

---

CA2331187C|2008-11-18|

---

EE04346B1|2004-08-16|

---

CA2331141A1|1999-11-18|

---

SK16812000A3|2001-08-06|

---

CN1137118C|2004-02-04|

---

BG64388B1|2004-12-30|

---

BR9911057A|2001-02-06|

---

AR016482A1|2001-07-04|

---

US6384030B1|2002-05-07|

---

MY122147A|2006-03-31|

---

PT1077976E|2002-12-31|

---

NO20005713D0|2000-11-13|

---

PL194085B1|2007-04-30|

---

SK286156B6|2008-04-07|

---

KR100593395B1|2006-06-28|

---

NO20005712D0|2000-11-13|

---

BG104933A|2001-10-31|

---

KR100575147B1|2006-05-03|

---

US6448244B1|2002-09-10|

---

MY120248A|2005-09-30|

---

AT221884T|2002-08-15|

---

ES2182531T3|2003-03-01|

---

EE200000657A|2002-04-15|

---

AU758876B2|2003-04-03|

---

CN1300287A|2001-06-20|

---

EP1077975B1|2003-04-23|

---

HU0102031A2|2002-05-29|

---

HRP20000740B1|2003-12-31|

---

CN1135229C|2004-01-21|

---

BG104717A|2001-07-31|

---

HRP20000741B1|2009-02-28|

---

CZ299481B6|2008-08-13|

---

CZ20004109A3|2001-05-16|

---

HU0103536A2|2002-07-29|

---

TWI259835B|2006-08-11|

---

IL139649D0|2002-02-10|

---

CN1300288A|2001-06-20|

---

CO5021227A1|2001-03-27|

---

DE69902461D1|2002-09-12|

---

HK1032781A1|2003-08-15|

---

SK16822000A3|2001-07-10|

---

DE69907171D1|2003-05-28|

---

ES2198915T3|2004-02-01|

---

EE200000651A|2002-04-15|

---

ZA200007173B|2002-03-04|

---

WO1999058529A1|1999-11-18|

---

IL139649A|2004-09-27|

---

NO20005713L|2001-01-11|

---

AU4141799A|1999-11-29|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1998-05-14|Priority to EP98201588.5

---

1998-05-14|Priority to EP98201588A

---

1999-05-06|Application filed by 디르크 반테, 얀센 파마슈티카 엔.브이.

---

2001-05-25|Publication of KR20010042852A

---

2006-05-03|Application granted

---

2006-05-03|Publication of KR100575147B1

优先权:

---

申请号 | 申请日 | 专利标题

---

EP98201588.5|1998-05-14|

---

EP98201588A|EP0957101A1|1998-05-14|1998-05-14|Water soluble azoles as broad-spectrum antifungals|